The role of ion
channels in high-grade glioma (HGG)
Panimaya Jeffreena Miranda 1,2*, Caitlyn
Richworth 1,3, Natalie Anderson 4,5,6
1 Telethon
Kids Cancer Centre, Telethon Kids Institute, University of Western Australia,
Perth, Western Australia, Australia.
2 Division of Paediatrics/Centre for Child Health Research, Medical
School, University of Western Australia, Western Australia, Australia.
3 School of Biomedical Sciences, University of Western Australia, Western Australia, Australia.
4 Perioperative Care Program, Perioperative Medicine Team, Telethon Kids
Institute, Nedlands, Australia
5 Division of Emergency Medicine, Anaesthesia and Pain Medicine, Medical
School, The University of Western Australia, Perth, Australia
6 Institute for Paediatric Perioperative
Excellence, The University of Western Australia, Perth, Australia
Corresponding Authors: Panimaya
Jeffreena Miranda
* Email: jeffybio@gmail.com
Abstract
High-grade glioma (HGG) is an aggressive brain
cancer with an overall 5-year survival rate of less than 10% in adults and less
than 2% in children. Despite significant research efforts, surgery combined
with chemo- and radiotherapy is the only treatment option available for these
patients. New targeted therapies such as kinase inhibitors, and combined
modalities fail in clinical trials due to the inability of drugs to cross the
blood-brain barrier, and HGG pathway rewiring. In vitro studies suggest that ion channels contribute to HGG
pathway rewiring and tumor survival. There are several United States Food and
Drug Administration-approved neurological drugs that readily cross the
blood-brain barrier and target ion channels. These drugs are readily available
on the shelf and can be easily repurposed to treat HGG. A systematic
understanding of the oncogenic roles of ion channels in patients with HGG will
help us to repurpose ion channel drugs to treat HGG. The study of the oncogenic
potential and therapeutic targeting of ion channels in HGG is still in the
early stage. This review summarises the findings that elucidate the expression
and oncogenic potential of ion channels in HGG patients. We have identified the
research gaps to translate ion channels as therapeutic targets for HGG.
Finally, we highlight the potential to use ion channel drugs as a single agent
or as part of combination therapy for the treatment of patients with HGG.
Keywords: High-grade glioma, Ion channels, Ion channel drugs, Tumor resistance, Drug
repurposing
Introduction
Glial cells form 50% of the cells in the central
nervous system where they support and protect neurons, form myelin, and
facilitate cellular homeostasis (1). About a third of all brain cancers originate from
glial cells and are known as gliomas. Gliomas are grouped based on their region
of origin, grades/pathological features, and aggressiveness. Based on the
region of origin, gliomas are subdivided as; diffuse intrinsic pontine glioma
(DIPG), astrocytoma, oligodendrogliomas, brain stem glioma, optic nerve glioma,
oligoastrocytoma, ependymoma (EPN) and glioblastoma multiforme (GBM) (2). Gliomas are classified as grades based on their
pathological features (grade I, II, III and IV). Highly diffusive and invasive
gliomas that belong to grades III and IV are collectively known as high-grade
gliomas (HGG) and they invade through the extracellular space in the brain and
central nervous system (3, 4).
The
diffusive nature of HGG makes complete surgical resection impossible (2, 5, 6). Hence, surgery followed by chemo- and radiotherapy
is the only treatment option for HGG patients, resulting in a very low 5-year
survival rate of <10% (7). As HGGs belong to stage III and IV, most patients
die within 18 months of diagnosis despite advances in treatment. Therefore the
only way to measure the therapeutic effectiveness of drugs is via the increased
survival rate of patients (8). HGG plasticity enables the tumor to rewire and
adapt its pathways for tumor growth and drug resistance (8–10) however, the key regulators that drive HGG plasticity
are not fully understood. This emphasises the need to identify novel
therapeutic targets to prevent HGG plasticity and increase the survival of
patients with HGG.
Recent advances in the field of HGG demonstrate a role
for ion channels in both HGG proliferation and invasion (11–13). Ion channels are membrane structures that regulate
the movement of ions across the cellular membrane to control various
physiological functions including brain cell function (14–18). Normal brain cells maintain a high degree of
plasticity to cope with continuous brain remodelling during memory formation
and to recover from various forms of brain cell injury (19–21). Ion channels are the key regulators of brain cell
plasticity that contribute to pathway rewiring in brain cells through their
structural and functional alterations (22). Research suggests that cancer cells hijack this
dynamic nature of ion channels to support their oncogenicity (23, 24). The role of ion channels in HGG tumors has been
demonstrated primarily through retrospective correlational studies of ion
channel aberrations and patient survival with genomic and proteomic studies
(101, 102). While in vitro studies
demonstrate that ion channel gene mutation and abnormal pore formation can
drive HGG tumorigenicity (reviewed in (25–28), (12, 29–31), some studies suggest that kinase pathways activates
ion channels in HGG (32). However, the functionality and oncogenic potential
of many ion channels remain unknown.
Repurposing ion channel drugs for HGG treatment may
represent an attractive therapeutic option for patients with HGG, as most
clinically approved ion channel drugs are used to treat neurological disorders,
and can easily cross the blood-brain barrier (BBB) (reviewed in (33)), (34). While literature does summarize the ability to
target ion channels as cancer therapy using laboratory models (reviewed in (35), there are few studies that discuss ion channel
expression patterns in HGG clinical/patient samples and correlate them with
therapeutic options (36). Therefore, this review will discuss: 1) ion channel
biology and its role in cancer, 2) expression and function of ion channels in
HGG clinical samples, 3) ion channel therapeutics to treat cancer, including
HGG and 4) areas for future research. We also briefly discuss ion channel
expression patterns identified in HGG clinical samples and their correlation
with patient prognosis and survival with relevance to the various types of ion
channels.
Overview of ion channel biology and its
role in cancer
Ion channels are integral membrane proteins that
maintain an electrochemical gradient for ion transport across cellular
membranes (37). Each ion channel comprises of multiple protein
subunits that are assembled together to form a pore-forming structure. This
process is known as ion channel biogenesis (38–40). The concentration of different intracellular ions
such as calcium, sodium, potassium and chloride play a key role in regulating
ion channel biogenesis (Figure 1) (41). Ion channel expression and function is highly
cell-type specific (37, 42, 43) (44). Ion channel expression is highly dependent on
biological processes including transcription, translation, protein processing, subunit
assembly and transportation of ion channel genes. Each cell type may express
more than ten different types of ion channels (45).
Figure 1. Regulation of ion
channel expression. Ion channel biogenesis is a multistep
process and is regulated by intracellular ionic concentration. Extracellular
ionic concentration is responsible to keep an ion channel either in the open or
closed state (41).
The function of an ion channel is dependent on its
activation state (reviewed in (44)) and ion channels can swing between both active and
inactive states (46). The activation state is regulated by multiple
factors including gating strategy and the channel orientation across the cell
membrane (reviewed in (47–51)). Multiple ion channels share common roles and
possess complementary and compensatory functions to effectively maintain the
cellular membrane potential (52). The ability of ion channels to constantly change
between their activation states make them particularly susceptible to malignant
transformation (53). For example, changes in the extracellular ionic
concentration results in an acidic tumor microenvironment that is demonstrated
to increase cell proliferation and invasion (38, 54), (reviewed in (55–57)). Genomic instability or protein dysfunction of ion
channels (58), (reviewed in (56, 59)) is the most common malignant transformation that
alters the activation state of ion channels. Their functions include altering
key intracellular processes such as transcription, cellular secretion and cell
volume to regulate cell proliferation, autophagy and cell cycle (60–62), (reviewed in (63–68) 69–72). Thus, ion channels are dynamic in their function and
undergo constant structural, functional, and activation changes to coordinate
and maintain an electrochemical gradient. Ligand binding, electrical flux or
voltage alterations or a combination of these maintains the activation state of
ion channels (73). Collectively, ion channels regulate the functioning
of vital organs such as cardiac muscles (reviewed in (74)) and synaptic transmission across neurons (reviewed
in (75)). Recent evidence demonstrates a role for ion
channels in cancer progression (Table 1) (76, 77) (reviewed in (56, 78, 79)). Cancer cells hijack ion channels for cellular
proliferation, invasion, metastasis, and drug resistance (80–82). Whole genome Pan-cancer analysis demonstrated ion
channel gene dysregulation in almost all cancer types with particular
In the context of HGG, in vitro proliferation and invasion assays demonstrate a role for ion channels in HGG progression (reviewed
in (13)). For instance, calcium (84–86) and calcium-induced potassium channels are involved
in HGG proliferation (87–90), (reviewed in (12)); potassium, chloride (91–93) and calcium-activated intermediate
(IK) potassium channels regulates HGG migration (4, 94) and sodium and chloride channels play a key role in
HGG drug resistance (31, 95, 96).
Table 1. Role of ion channels in cancer progression.
Cancer type |
Ion channel type |
Genes involved |
Oncogenic phenotype |
Reference |
Nasopharyngeal |
Transient Receptor Potential Cation Channel Subfamily M |
TRPM7 |
Cell migration |
(202) |
Calcium-sensitive
chloride channel |
CIC-3 |
Cell
proliferation |
(175) |
|
Esophageal squamous cell |
voltage-dependent potassium channel (Kv) |
hERG1 |
Proliferation, stem cell growth |
(203) |
Transient
Receptor Potential Cation Channel Subfamily V |
TRPV2 |
Proliferation
and drug resistance |
(204) |
|
Transient Receptor Potential Cation Channel Subfamily C |
TRPC6 |
Poor patient prognosis |
(203) |
|
calcium
release-activated calcium channel protein 1 |
Orai1 |
Cell
proliferation |
(205) |
|
Thyroid |
Transient Receptor Potential Cation Channel Subfamily C |
TRPC1 |
Cell proliferation and migration |
(206) |
voltage-dependent
potassium channel (Kv) |
hERG1 |
Cell
migration |
(206) |
|
Breast |
melastatin channels |
cellular invasion |
(207) |
|
voltage-sensitive calcium-activated
chloride channel |
TMEM16A |
Cell
proliferation |
(208) |
|
Transient Receptor Potential Cation Channel Subfamily V |
TRPV2 |
Revert drug resistance |
(209) |
|
Nav1.5 |
Tumor
Metastasis |
(164) |
||
Potassium voltage-gated channel |
Kv10.1 (EAG) |
Cell proliferation and migration |
(210) |
|
small
conductance calcium-activated potassium channel |
KCa 2.3 |
Cell
migration |
(211) |
|
Renal cell |
Transient Receptor Potential Cation Channel Subfamily M |
TRPM3 |
Promotes cell growth |
(212) |
Transient
Receptor Potential Cation Channel Subfamily C |
TRPC6 |
Cell
proliferation and aggressiveness |
(213) |
|
calcium release-activated calcium channel protein 1 |
Orai1 |
Cell proliferation and migration |
(214) |
|
small
conductance calcium-activated potassium channel |
KCa3.1 |
Highly
metastatic and reduced progression-free survival |
(215) |
|
Colon |
Intracellular chloride channel |
CLIC1 |
Cell invasion and migration |
(216) |
Transient
Receptor Potential Cation Channel Subfamily C |
TRPC1, Orai1 |
Cell
migration |
(203) |
|
Nav1.5 |
Poor patient prognosis |
(217) |
||
small
conductance calcium-activated potassium channel |
KCa3.1 |
Proliferation
and invasion |
(218) |
|
Ovarian |
Intracellular chloride channel |
CLIC1 |
Intraperitoneal metastasis |
(219) |
Transient
Receptor Potential Cation Channel Subfamily C |
TRPC3 |
Cell growth |
(220) |
|
Nav1.5 |
Cell metastasis |
(221) |
||
Cervical |
voltage-dependent
potassium channel (Kv) |
hERG1 |
Cell
proliferation |
(222) |
NaV 1.6 |
Higher invasive potential |
(223) |
||
Melanoma |
voltage-dependent
potassium channel (Kv) |
hERG1 |
Tumor
metastasis |
(224) |
Bladder |
Transient Receptor Potential Cation Channel Subfamily M |
TRPM7 |
Proliferation, recurrence, metastasis and invasion |
(221,225) |
Prostate |
Transient
Receptor Potential Cation Channel Subfamily M |
TRPM4, 8 |
Enhanced
survival, proliferation, cellular invasion |
(207) |
Intracellular chloride channel |
CLIC1 |
Cell proliferation and metastasis |
(226) |
|
Potassium
channel subfamily K member 2 |
TREK-1 |
Reduced
castration resistance-free survival |
(227) |
|
Nav1.7 |
Tumor metastasis |
(228) |
||
Intracellular
chloride channel |
CLIC1 |
Cell
migration and proliferation |
(229) |
|
Transient Receptor Potential Cation Channel Subfamily M |
TRPM8 |
Tumor proliferation and growth |
(230,231) |
|
Gastric |
voltage-dependent
potassium channel (Kv) |
hERG1 |
Survival and
cell invasion |
(203) |
Transient Receptor Potential Cation Channel Subfamily M |
TRPM7 |
Cell proliferation |
(184) |
|
Intracellular
chloride channel |
CLIC1 |
lymphatic
invasion, lymph node metastasis and perineural invasion |
(232) |
|
calcium release-activated calcium channel protein 1 |
Orai 1 |
Cell metabolism, migration and invasion |
(233) |
|
Nav1.7 |
Cell
proliferation and invasion |
(234) |
||
voltage-dependent potassium channel (Kv) |
hERG1B (Kv11.1) |
Reduced survival, metastasis |
(235) |
|
Hepatocellular |
Transient
Receptor Potential Cation Channel Subfamily C |
TRPC1 |
Cell
proliferation |
(236) |
Intracellular chloride channel |
CLIC1 |
Poor prognosis |
(237) |
|
small
conductance calcium-activated potassium channel |
KCa3.1 |
Cell
proliferation and migration |
(238) |
|
Glioma |
small conductance calcium-activated potassium channel |
KCa3.1 |
Tumor invasion |
(239) |
Transient
Receptor Potential Cation Channel Subfamily C |
TRPC6 |
Hypoxia-induced
aggressive tumor and angiogenesis |
(240) |
|
Transient Receptor Potential Cation Channel Subfamily C |
TRPC1,3,5 |
Cell proliferation |
(241) |
|
Intracellular
chloride channel |
CLIC1 |
Reduced
patient survival |
(180) |
|
voltage-dependent calcium channel L-type, alpha 1C subunit |
Cav1.2 |
Cell Proliferation |
(242) |
|
Cav2.1 |
Progression
of tumor growth |
(216) |
||
Voltage-gated potassium channel |
Mitochondrial Kv1.3 |
Cell survival |
(243) |
|
ATP driven
potassium channel |
Katp |
Radio
resistance |
(244) |
Additionally, in
vitro models demonstrate a distinct role for calcium, potassium, sodium,
and chloride ion channels in regulating HGG progression and cellular
homeostasis compared to glial cells (reviewed in (97, 98)) (Figure 2). Multiple ion channels coordinate
together to balance ionic flux, making it complicated to tease apart their
mechanism of oncogenesis. For example, Ca2+-activated K+ (BK) channel
co-localize with ClC-3 Cl− channels to initiate brain metastasis (4).
However, there is limited pre-clinical evidence to demonstrate the oncogenic
potential of ion channels and the anti-tumor efficacy of ion channel drugs in
HGG tumors (99,100). On the other hand, ion permeating proteins are a
common drug target. A pan-cancer analysis identified ion permeating proteins
are highly expressed in a group of cancer samples of HGG (83).
Expression and function of ion channels in HGG
The success of translational research depends on its
ability to mimic clinical conditions in the research environment. Ion channel
abnormalities in HGG patient samples have been demonstrated by genomic and
proteomic analyses. Genome-wide analysis of HGG tumor samples reveals that up
to 90% of all HGG tumors harbour mutations in ion channel genes (29). These findings are in line with evidence from
genome-wide analysis of HGG stem-like cell exon sequencing, which also
identified distinct ion channel gene mutations in HGG tumor-derived stem-like
cells (101). The Repository of Molecular Brain Neoplasia Data
(REMBRANDT) is a comprehensive database that has mapped the gene expression and
copy number arrays of HGG alongside clinical phenotypic of HGG tumor samples. A
dataset study on REMBRANDT revealed a HGG-specific ion channel gene expression
signature (56 genes overexpressed out of a panel of 251 genes) which included
genes from a range of different families of ion channels (102). This gene signature was validated in an independent in vitro study using pharmacological
knock-down or genetic knock-down mouse models. This study demonstrated that the
expression of the identified ion channel gene signature enhanced HGG growth in
culture (101). In addition, whole-genome HGG tumor analysis has
identified a range of ion channel abnormalities including mutations across
different families of ion channels in calcium, sodium, potassium, and chloride
channels (101). The below section discusses studies that correlate
ion channel gene expression with HGG progression.
Calcium channels
Calcium channels were one of the first identified
oncogenic ion channels to play a role in the pathogenesis of HGG (59). In vitro
studies demonstrate that an increase in intracellular calcium contributes to an
increase in HGG proliferation, and inhibition of the T-Type Calcium channel
prevents HGG growth and metastasis (103). Cav3.2 is a gene that codes for the
T-type calcium channel and increases intracellular calcium levels by opening
T-type calcium channels during membrane depolarization. Zhang and colleagues (104) analysed HGG patient data from both The Cancer Genome
Atlas (TCGA) and REMBRANDT databases and identified that 11% of patients either
had a mutation, or mRNA upregulation or amplification in the Cav3.2
genes (102,104). Suggesting, potential aberrations within Cav3.2
may have driven the oncogenicity of T-Type calcium channel and contributed to
poor patient survival in this cohort of patients (104).
Sodium Channels
Joshi et al used tumor genome sequencing information
and correlated the presence of sodium channel mutations with a decreased median
survival of HGG patients (30). This finding validates other studies that identify a
role for activated sodium channels in HGG tumor progression (101). Acid-sensing ion channels (ASIC) are a type of sodium channel that are voltage
insensitive in both neuronal and glial cells and can detect ionic alterations
in the extracellular environment (105). ASIC expression maintains HGG cells in a depolarised
state, making them susceptible to malignancy (reviewed in (106)).
Co-expression of ASIC1 and ASIC2 suppressed sodium
influx in normal brain astrocytes.
However, the sodium influx suppression was absent in HGG tumor samples.
mRNA expression analysis of the HGG tumor samples showed the absence of ASIC2 genes led to the increase in sodium
influx (107). Similarly, an independent study by Tian and
colleagues identified high expression of ASIC1, and ASIC3, in addition to low
expression of ASIC2 in the HGG patient tumor dataset from REMBRANDT (108). Further in vitro testing on HGG stem cells
demonstrate that the co-expression of ASIC2 and ASIC3 resulted in the
suppression of the oncogenic potential of ASIC3 (108). Nav 1.6 is a sodium channel membrane
protein mainly concentrated in the sensory and nervous systems (109). Recent drug screening analyses identified oncogenic
potential for Nav 1.6 in HGG cells
Potassium channels
Evidence in exploring the oncogenic role of potassium
channels in neurological cancer are starting to emerge (111). Potassium channels can co-assemble with multiple
other channels and form the most complex class of ion channels (112). In normal astrocytes, voltage-gated potassium
channels, Kv1.5 and Kv1.3, have been shown to have a role in cell proliferation
and growth (113,114). This is demonstrated in a 2017 study, where novel
Kv1.3 inhibitors (PAPTP or PCARBTP) induced massive cell death in HGG cells.
Another study investigating the expression of these channels in HGG samples
demonstrated differential expression of Kv1.5 in HGG according to subtype and
malignancy grade, while Kv1.3 did not (113). Interestingly, Arvind and colleagues (115) identified overexpression of Kv1.5 protein, a
voltage-gated potassium channel, in low-grade gliomas directly correlated with
better patient survival. Thus, Kv1.5 protein expression has been identified as
a good prognosis marker for low-grade gliomas.
Another potassium channel, Kir4.1, is specifically
located on the cell membrane of astrocytes, attaching to blood vessels and
forming synapses. A study found that Kir4.1 expression is decreased in HGG and
resulted in increased cell invasion, however, the mechanism by which this
occurs has not been elucidated (116). It is hypothesized that Kir4.1 expression may favour
the assembly of cytoskeletal proteins in the filopodia and hence, increase cell
invasion. Kir4.1 also facilitates cellular differentiation in normal
astrocytes. These channels are upregulated in terminally differentiated
astrocytes and are downregulated in immature proliferative astrocytes ((117) 113). Therefore, it is suggested that the
downregulation of these channels in HGG may contribute to unrestrained growth
and proliferation. Kir4.1 facilitates cellular differentiation in normal
astrocytes, and is not expressed in proliferative astrocytes as this prevents
cells from post-mitotic transition (118). In contrast, Kir4.1 channels in HGG cells are
localised on the nuclear membrane and are absent in the cell membrane
Chloride channels
Chloride transportation is critical for normal
cellular functioning (119). Chloride flux contributes to cell proliferation and
cell division via cell volume regulation (120). In HGG, chloride channels have been identified to
increase proliferation and drug resistance (96). Increased expression of chloride channels in HGG
tumor samples correlated with reduced patient survival (96). Wang and colleagues compared tumors from grades I-IV
and identified two chloride channel genes (chloride intracellular channel 1 (CLIC1)
and chloride intracellular channel 4 (CLIC4)) to be upregulated in grade IV
tumors and in paediatric brain cancer (121). This suggests oncogenic roles for CLIC1 and CLIC4 in
aggressive HGG and its contribution to radio-resistance (122). Similarly, in an independent study, upregulation of
mRNA transcript levels of CLIC1 in HGG patient tumors correlated with poor
patient survival (123). Furthermore, the expression of CLIC1 and CLC3 in HGG
tumors correlated with chemotactic metastasis and drug resistance (123).
In vitro mechanistic knockdown studies suggest a role for
CLIC3 in HGG proliferation and metastasis. Activation of CLC-3 by the
Ca2+/calmodulin-dependent protein kinase II enhanced the HGG cellular
condensation during cell division, suggesting a role for CLC-3 in HGG
proliferation (124). NF-κB is an oncogenic transcription factor that
increases the transcription of matrix metalloproteinases MMP-3 and MMP-9 for
cell migration in HGG (125). CLIC3 interacts with
Ca2+/calmodulin-dependent protein kinase II to enhance the oncogenic
transcriptional activity of NF-κB for cell migration (126). NKCC1 is a form of cotransporter protein that facilitates
active transport of chloride, sodium, and potassium ions. In HGG, NKCC1 accumulates
high concentrations of intracellular Cl− which is known to be utilised by HGG
cells during invasion (127) suggesting a role for chloride channels and
transporters in regulating HGG cell volume for oncogenesis (128).
Miscellaneous channels
Besides the four major ion channels, there are other
minor channels including transient receptor potential melastatin (TRPM) (129), transient receptor potential canonical (TRPC),
purinergic receptors (PRX) and human ether-a-go-go related gene (hERG). These
minor channels have distinct expression patterns in HGG patient cohorts which
correlate with patient survival. For example, a recent study concluded that
overexpression of TRPM3 and P2RX4 directly correlated with reduced survival of
patients with HGG (101). In contrast, Alptekin and colleagues (130) analyzed the survival of 33 patients with HGG and
identified that patients who survived longer than 12 months expressed high
transcripts of TRP channel genes (TRPC1,
TRPC6, TRPM2, TRPM3, TRPM7, TRPM8, TRPV1, and TRPV2). This suggests that the expression of some of the transient
channels in patients with HGG may be indicative of a good prognosis (130). Similarly, P2X7R, an ATP-gated cation-permeable
receptor, was highly expressed in a subset of HGG patient tumor biopsies. The
expression of these receptors were correlated with disease-free overall patient
survival, and a positive response to radiotherapy (131). In addition, over-expression of gamma-aminobutyric
acid type A receptor subunit gamma (GABRG3) in HGG tumors is suggestive of an
increased mean patient survival (101). Overall, these findings suggest that ion channels
can also be used as biomarkers for positive prognoses (increased patient
survival). Knockdown studies suggest a role for mechanosensitive ion channel
Piezo2 in glioma chemo resistance (132). Piezo2 is also identified to be overexpressed in
patient fatality caused by peritumoral brain edema (133). Table 2 summarizes the different ion channel
families, their roles in HGG, along with potential targeting strategies.
Table 2. Clinically approved ion channel
drugs.
Ion channel targeting |
Drug |
Treatment |
Reference |
Sodium channel blockers |
Tetrodotoxin
(TTX) |
Pain relief |
(304) |
voltage-dependent
sodium channel |
lignocaine and Novocaine |
Anaesthetics |
(305,306) |
voltage-dependent sodium channel |
Lidocaine, Flecainide,
Propafenone |
Antiarrhythmic drugs |
(307) |
voltage-dependent
sodium channel |
Phenytoin,
fosphenytoin, Lacosamide, Valproate, Zonisamide |
Antiepileptic |
(308) |
voltage-dependent sodium channel |
Lacosamide |
Anticonvulsant |
(309) |
Sodium
potassium channel blockers |
phenytoin,
topiramate, lamotrigine and carbamazepine |
Antiepileptic |
(310–312) |
Voltage-gated L-type calcium channel blockers |
verapamil, diltiazem, nimodipine, nifedipine and amlodipine |
Angina |
(313) |
Potassium ATP
channel agonist |
vasodilator,
and nicorandil |
Angina |
(314) |
sodium and potassium channels |
Amiodarone |
Antiarrhythmic |
(315,316) |
Voltage-gated
calcium channel blockers |
verapamil,
amlodipine and nifedipine |
Hyertension |
(317) |
potassium channel activator |
diazoxide |
Vasodilation during hypertension |
(314) |
Regulator of
intracellular calcium levels |
Nicotinic
acid (NA) |
Atherosclerosis. |
(318) |
K ATP channels blocker |
sulphonyl urea drugs – glibenclamide |
Diabetes |
(319) |
selective
inhibitor of Kv1.3 |
Margatoxin
(MgTX), |
Non-small
cell lung cancer cell |
(320) |
antagonist of TRPM8 |
cannabigerol (CBG) |
Colon cancer cells |
(321) |
VGSC-blocking
drug |
phenytoin |
Breast cancer
in vitro |
(164) |
potassium channel blocker |
Oxaliplatin |
Anti-proliferative effects on HGG, colorectal cancer in vitro |
(322) |
Kv channels
blocker |
PAPTP and
PCARBTP |
Glioma cells
in vitro |
(243) |
InaP blockers |
ranolazine and riluzole |
Metastatic breast and prostate cancer |
(197,233,23) |
Multi-channel
blocker, Potassium channel modulator |
Hydroquinidine |
Currently
used to treat short-QT and Brugada arrhythmia syndromes Significant
antiproliferative and pro-apoptotic effect on TMZ-sensitive and -resistant
HGG cells |
(325) |
Sodium channel blocker |
Oxcarbazepine |
FDA-approved antiepileptic drug Anti-proliferative and pro-apoptotic in IDH mutant glioma stem
cells |
(326) |
EAG2-Kvβ2
complex blocker |
Designer
peptide against EAG2-Kvβ2 complex |
Anti-proliferative
in patient-derived xenograft and syngeneic mouse models |
(327) |
SK2 channel blocker |
P01 scorpion toxin |
Anti-proliferative in U87 glioma cells |
(328) |
hERG channel
opener and potassium modulator |
NS1643 –
small molecule inhibitor |
Combinations
of Pantoprazole with TMZ, retigabine and NS1643 had anti-proliferative
in U87 cells |
(182) |
Potassium channel opener |
Retigabine - FDA-approved epilepsy drug |
||
proton-pump
inhibitor |
Pantoprazole
- FDA-approved proton-pump inhibitor |
||
Calcium channel blocker |
Flunarizine - Not FDA-approved. Used to treat
migraines |
Anti proliferative effect and inhibit invadopodium |
(329) |
Calcium
channel blocker |
Econazole
nitrate - Anti -fungal drug |
||
Potassium channel blocker |
Quinine hydrochloride - Anti-malarial drug |
||
Potassium
channel Kv1.3 blocker |
PAPTP/PCARBTP |
Anti-proliferative
in HGG cells |
(243) |
T-type/L-type calcium channel blocker |
Mibefradil was used to treat hypertension. Currently
withdrawn from market |
Suppressed HGG growth and stemness |
(104) |
Potent TRPC
antagonist (TRP3-7) |
Compound 15g |
Anti-proliferative
effects in HGG |
(254) |
hERG antagonist/ligand |
Doxazosin - Treatment for benign prostatic hyperplasia |
Anti-proliferative effects in HGG |
(269) |
hERG
antagonist/ligand |
letrozole -
Phase I clinical trial |
Anti-proliferative
effects in HGG |
(270) |
AMPAR (calcium permeable channels) |
Fluoxetine - FDA approved antidepressant |
Anti-proliferative effects in HGG |
(238) |
Sodium/potassium/chloride
co-transporter isoform 1 (NKCC1) |
STS66
Bumetamide derivative |
Anti-proliferative,
reduced cell growth in HGG |
(330) |
TRPV4 antagonist |
Cannabidiol |
Anti-proliferative in HGG |
(331) |
Collectively, there is evidence demonstrating ion
channel aberrations in HGG tumors. Some ion channels play an oncogenic role
while others may be tumor suppressive and each of the ion channel family
members can contribute to a particular hallmark of cancer. For example,
inhibiting sodium channels can prevent tumor cell invasion while inhibiting
calcium channels may trigger an anti-proliferative effect. However, ion channel
aberrations have only been retrospectively correlated with the survival of
patients with HGG and an in-depth mechanistic understanding of their oncogenic
roles in HGG is lacking. The current research gap between pre-clinical testing
and the clinical understanding of HGG tumors
has limited the effective translation of research findings for HGG
treatment and will be discussed below.
Overview of ion channels therapeutics in
cancer
Every cell has ion channels and ion transporters along
their plasma membrane to transport ions across the cells. Each type of cell
possesses specific ion selectivity and permeability making their ionic
composition different from one another and from their microenvironment (134). This ionic difference creates a membrane potential (Vm) to the cell membrane (135). The change in Vm
in turn regulates the movements and function of the cellular proteins to drive
cellular activities such as proliferation, invasion and differentiation. The
ionic exchange is necessary to regulate cellular volume, a critical factor in
cell cycle and cell invasion (136). Cardiovascular, anaesthetic and many psychiatric
drugs target ion channels (74,137–139). A faster approach to translational medicine is to
repurpose drugs. Drug repurposing is a process that has been largely used for
neurological disorders. Ion channel drugs have been used to treat various
neurological disorders at different treatment regimens (140). The recent developments in high-throughput assays
and technologies such as flux-based assays, fluorescence-based assays and
automated electrophysiological assays have drastically changed the outlook of
using ion channel drugs to treat “channelopathies” such as Bartter Syndrome, seizures and cystic fibrosis through ion-channel-specific assays (47,141,141–146). There are many clinically approved ion channel drugs
to treat neurological disorders (147), neuronal damage (148), cardiovascular damage, cardiac disease, hypertension, diabetes, epilepsy,
spinocerebellar ataxia type-13, infectious diseases (149), and brain defects (150). These drugs can effectively cross the blood-brain
barrier and the majority are classified as anticonvulsant drugs or calcium and
sodium channel blockers (33,151). As a result, ion channel drugs are being tested to
treat a range of diseases, disorders and cancers, including HGG (Table 3).
Table 3. Role of ion channels in HGG and potential targeting
strategies.
Ion channel name |
Ion channel type |
Genes involved |
Oncogenic Phenotype |
Potential targeting strategy |
Reference |
Cav3.1 |
Voltage-gated
calcium channels T-type, alpha 1G subunit |
CACNA1G |
Increased
proliferation and regulation in autophagy |
Cardiac
arrhythmia, epilepsy, hypertension drugs can be used |
(245) |
Cav3.2 |
Voltage-gated
calcium channels T-type, alpha 1G subunit |
CACNA1H |
Increased
proliferation through AKT/mTOR pathways |
Pain, and
epilepsy drugs can be tested |
(104,246,247) |
Cav2.1 |
Voltage-dependent
P/Q type |
CACNA1A |
Increased
proliferation |
Epilepsy, and
migraine drugs can be used to target |
(241) |
Cav1.2 |
Voltage-dependent
L-type |
CACNA1C |
Increased
proliferation |
Cardiovascular
drugs |
(248) |
TRPC1, 5 |
Transient receptor
potential cation channel, subfamily M, member 1 and 5 |
TRPC1, TRPC5 |
Increased
proliferation through regulation of calcium signalling and increased
migration |
Riluzole TRPC5
agonist approved drug for the treatment of amyotrophic lateral sclerosis can
be used in HGG |
(249–251) |
TRPM8 |
Transient
receptor potential cation channel, subfamily M, member 8 |
TRPM8 |
Increased
proliferation, and migration mediated by BK activation |
Anti‐inflammatory
drugs targeting TRPM8 can be used to target HGG |
(252,253) |
TRPM7 |
Transient
receptor potential cation channel, subfamily M, member 7 |
TRPM7 |
Increased,
proliferation, migration and invasion |
(253–255) |
|
TRPC6 |
Transient
receptor potential cation channel subfamily C member 6 |
TRPC6 |
Increased
proliferation, regulation of cell cycle, hypoxic migration |
(203,256) |
|
CLIC1 |
Chloride
intracellular channel protein 1 |
CLIC1 |
Increased
proliferation |
Biotin
conjugated analog of MTI-101 can target CLIC1 to reduce HGG proliferation |
(180,257) |
CLC3 |
Chloride
voltage-gated channel 3 |
CLCN3 |
Increased
migration and invasion |
Inducible
gene deletion strategies can help target CLCN3 to reduce HGG migration and
invasion |
(124,126,258) |
TRPML2 |
Mucolipin-2
transient receptor potential cation channel |
MCOLN2 |
Increased
proliferation and decreased apoptosis |
TRP channel
inhibitors such as Capsaicin, SKF-96365 and 2-APB can target MCOLN2 in HGG |
(259–262) |
TRPV4 |
Transient
receptor potential vanilloid 4 |
TRPV4 |
Increased
migration and invasion, cytoskeletal remodelling |
Orally active pulmonary edema drug targeting TRPV4 can reduce HGG
migration |
(263–265) |
Kv1.3, Kv1.5 |
Voltage-gated
potassium channel |
KCNA3, KCNA5 |
Increased
proliferation |
Kv1.3
specific toxins such as charybdotoxin and margatoxin can be used to prevent
HGG proliferation |
(266–268) |
Kv2.1 |
Voltage-gated
potassium channel |
KCNB1 |
Increased
proliferation, regulation of autophagy |
Antiarrhythmic
drugs such as Quinidine, 4-Aminopyridine (4-AP) and potassium channel
blocker, Tetraethylammonium, are
specific blockers of Kv2.1 |
(70,113,126) |
Kv11.1 (hERG) |
Ether-a-go-go
potassium channel |
KCNH2 |
Increased
proliferation |
Dofetilide an
anti-arrhythmic drug and E-4031 a well known hERG channel blocker may reduce
proliferation in HGG |
(224,269–271) |
VRAC |
Volume-regulated
anion channel |
LRRC8A |
Hypoxia-related
proliferation and survival |
Small
molecule inhibitors such as DCPIB or LRRC8A specific antibodies are good
therapeutic opportunities for HGG |
(27,272–274) |
Nav1.6 |
Voltage-gated
sodium channel |
SCN8A |
Increased
proliferation, migration and invasion |
Small
molecules like PF-06372865 and GS967 have been shown to selectively inhibit
SCN8A. |
(110,275) |
Nav1.5 |
Voltage-gated
sodium channel |
SCN5A |
Increased
invasion with NHE1 |
Multiple
antiarrhythmic and antianginal drugs such as Amiodarone, Ranolazine, Quinidine, Mexiletine, Lidocaine,
Flecainide can target SCN5A in HGG |
(51,276,277) |
AMPAR |
Calcium
permeable channels |
GLUA1 and
GLUA4 |
Increased
proliferation and invasion |
Selective GLUA1 inhibitor - LY3130481 and
GLUA4 inhibitor such as CX614 and Cyclothiazide |
(238,278–280) |
ANO1, TMEM16A |
Anoctamin 1
voltage-gated calcium-activated anion channel |
TMEM16A |
Increased
proliferation, supports maintenance of stemness in GSCs |
Anoctamin 1
inhibitors such as T16Ainh-A01 and CaCCinh-A01 can reduce GSC stemness |
(281–283) |
ASIC1 and
ENaC |
Acid-sensing
ion channel 1a |
ASIC1 |
Increased
migration and lamellipodium expansion |
Amiloride is
a well-known diuretic that blocks epithelial sodium channels |
(284–286) |
Kir4.1 |
ATP-sensitive
inward rectifier potassium channel 10 |
KCNJ10 |
Decreased
proliferation |
Baicalein is
a flavonoid compound that effectively inhibit KCNJ10 can be used to treat HGG |
(118,287,288) |
KATP, Kir6.2 |
ATP-sensitive
potassium channels |
KCNJ11 |
Increased
proliferation |
Glyburide, a
KATP channels blocker currently in the clinic to treat neonatal diabetes
caused by KCNJ11 mutations can be used to reduce HGG proliferation |
(289–291) |
KCa1.1, BK |
Calcium-activated
potassium channel subunit alpha-1 |
KCNMA1 |
Increased
proliferation and migration |
Clinically
available epileptic drug such as Paxilline blocks KCNMA1 |
(292–294) |
KCa3.1 |
Intermediate-conductance
calcium-activated potassium channel |
KCNN4 |
Increased
migration and invasion |
Senicapoc
(ICA-17043) is a KCa3.1 channel blocker, that reduces hemolysis and improving
red blood cell survival in patients with sickle cell anemia. This drug may
reduce HGG migration by blocking KCa3.1 with minimal side effects |
(97,292,295) |
PIEZO1 |
Mechanosensitive non-specific cation channel |
PIEZO1 |
Increased
proliferation, regulation of tissue stiffness and aggression |
There are no
clinically approved drugs to treat PIEZO1 channel. GsMTx4 is a peptide toxin
derived from tarantula venom and is potent to inhibit PIEZO1. |
(296–298) |
NHE5 |
Na+/H+
exchanger 5 |
SLC9A5 |
increased
proliferation, metastasis, cell adhesion and invasion |
There are no
selective inhibitors for NHE5. NHE1 inhibitors such as Amiloride and its
derivatives can be used to reduce HGG growth and metastasis. |
(57,299) |
NHE9 |
Endosomal pH
regulator |
SLC9A9 |
Increased
proliferation, stemness |
There are no
selective inhibitors for NHE5. NHE1 inhibitors such as Amiloride and its derivatives
can be used to reduce HGG growth and metastasis. |
(57,300,301) |
NKCC1 |
Na+K+/Cl-
cotransporter isoform 1 |
SLC12A2 |
Increased
proliferation, migration, invasion |
Bumetanide
and Furosemide are loop diuretic that inhibits NKCC1 and is used primarily to
treat edema and hypertension. This can be tested on HGG for anti-cancer
effects. |
(302,303) |
Electrophysiological analysis of cancer cells
demonstrate depolarization of the cancer cell membrane which contributes to the
stemness of cancer cells and attribute to the cellular proliferation, invasion
and migration (109, 135, 152). Studies using hepatoma and adenocarcinoma demonstrates
increased intracellular sodium concentration compared to normal cells,
suggesting a role for cancer cell depolarisation (153, 154). More recently, ion channels have been identified as
a target for cancer therapy with a few reviews summarising their role as a
therapeutic target for cancer (55,155,156). Ion channel drugs modulate ion channels by either
blocking or opening them, altering the ionic concentration and in turn, reducing
the function of oncogenic proteins across cancer cells (157,158). However, the drugs may have different modes of
action in different types of cancer due to their diverse oncogenic function and
their complex interactions between other ion channels and oncogenes (159,160). Once the altered channels are identified in any
given cancer, treating the alteration using modulators will recalibrate the
ionic balance and alter the Vm to reduce the oncogenic potential (161). Some of these drugs have been used in pre-clinical
models to demonstrate their anti-cancer effects (162–164). Based on drug repository screening in silico, a study screened over 100
United States Food and Drug Administration (FDA) approved drugs against small
cell lung cancer (SCLC) (165). Of the top 100 drugs identified, many were ion
channel modulators such as imipramine, promethazine and verapamil, that
significantly inhibited the growth of SCLC both as a single agent (165) and in combination (166). However, these drugs were specific to SCLC and did
not add any survival benefit in a phase III study in patients with
multidrug-resistant multiple myeloma (167). This suggests that ion channels may interact with
other pathways specific to the cellular context and hence, studying ion channel
drugs in the presence of other oncogenic drivers may be a greater determinant
of drug efficacy. Further, the clinical availability of multiple ion channel
drugs means a shorter translation time and a higher rate of clinical success,
underlining the need for additional research to identify roles of ion channels
in HGG tumors. However, there is limited literature exploring the opportunity
of repurposing ion channel drugs for cancer therapy (36).
Therapeutic targeting of ion channels in
HGG
HGGs are commonly treated with alkylating agents (such
as temozolomide) (168,169) and ionizing radiation (168,170) that causes DNA damage and induce apoptotic cell
death (168). However, HGG tumors develop resistance to standard
treatments due to pathway rewiring, resulting in mortality. Chemo- and
radiotherapy-induced DNA damage triggers a series of tumor-cell survival
mechanisms including alterations in calcium-activated potassium channels and
calcium-permeable non-selective cation channels (95). Ion channels are active
in excitable cells such as neurons and possess cell-specific functions (133). In vitro analyses demonstrate that
Ion channel drugs as single-agent therapy
in HGG
CLC-3, a voltage-gated chloride channel, is present in
the plasma and intracellular membrane of HGG cells (175) and is predicted to drive drug resistance (96).
Chlorotoxin (Cltx) preferentially inhibits HGG cell invasion by binding to
CLC-3/matrix metallopeptidase 2 (MMP2) membrane complex and inhibits the
enzymatic activity of MMP2 to reduce the cell surface expression levels of MMP2
to inhibit cell invasion. Cltx has recently entered phase I and II clinical
trials for patients with HGG (176). Similarly, I-TM-601, a synthetically labelled Cltx,
has also entered phase I and II clinical trials for patients with HGG tumors (177). Besides its therapeutic potential, radiolabelled
I-TM-601 has also been used as a diagnostic marker in identifying tumor burden
in patients with HGG. Radiolabelled I-TM-601 can be effectively detected using
whole-brain single-photon emission computed tomography scans (178) and immunohistochemistry of brain tissue (179). Another study tested the efficacy of a therapeutic
antibody against CLIC1 in a pre-clinical study using HGG derived progenitor
cells where the antibody significantly increased survival in mouse models (180).
Ion channel drugs as part of combination
therapy in HGG
Multiple independent oncogenic pathways combine to
trigger the hallmarks of cancer. Combination therapy is, therefore, the gold
standard for cancer treatment (181). Ion channel drugs that failed as a single-agent
treatment have been shown to increase survival benefits when used as
combination therapy in HGG clinical trials (182). Amiodarone, an anti-arrhythmic drug
Although these studies are preliminary and not all
drugs have been tested in pre-clinical animal models, the findings highlight
the potential in repurposing ion channel drugs as a treatment for patients with
HGG. However, to date, studies investigating the role of ion channels in HGG
survival have been associational, not mechanistic and further studies are
necessary to identify the mechanistic role for ion channels as a potential
therapeutic target for HGG. Pre-clinical testing of ion channel drugs on clinically
relevant HGG models will expedite the clinical translation of FDA-approved ion
channel drugs as both single and in combination with conventional therapies, in
both adult and paediatric patients with HGGs, which may otherwise cause severe
neurological side effects (192).
Research gaps in repurposing ion channel
drugs for cancer therapeutics – preclinical model development
Historically, limitations of both in vivo
animal studies and 2D in vitro models have delayed progress in this
field (193). 2D immortalized monolayer cell culture have been
used due to their cost effectiveness and reproducibility. However, they do not
accurately reflect the tumor environment, the highly heterogeneous nature of
HGG nature. Since the announcement by the United States Food and Drug
Administration in 2022 to abolish the mandate to test on animals, (through the FDA Modernization Act 2.0)
in vitro methods and models are
rapidly advancing in this area (193–195). Non-animal models include 2D cell culture, 3D
spheres (or neurospheres), organoids, bio printing, tissue-slice cultures and
tumor-on-chip methods, all which have advantages and disadvantages (194,195). To account for the highly heterogeneous nature of
HGG and for in vitro studies to be
reflective of clinical outcomes, it is important to use patient-derived cell
lines. Development of 3D in vitro models that can incorporate
vasculature and immune cell components will advance this field (194). Tumor-on-chip is both dynamic and can incorporate
vasculature by joining multiple organ (organ-on-chip) systems. Alternatively,
culturing 3D spheroids in a chip environment provides a more dynamic and
physiologically accurate model, which has already been used to test certain FDA
approved drugs for repurposing (196). More complex models have been developed since,
integrating biosensor enhanced on-chip models (197). Complex scaffolding models utilising biomaterials
have been developed to overcome some of the limitations of current models (195). Bio-banking will be essential to advance these
preclinical models. The use of preclinical models using patient-derived cell
lines can help investigate the mechanism of action and thereby, improve the
translation of research findings. Further improvements must focus on the
accurate recapitulation of the tumor microenvironment (including electrical
stimulation) and the range and plasticity of cellular states of HGG among
others (198). Combining the knowledge gleaned from computational
simulation of ion channel biology can further improve in vitro models,
particularly for tissue engineering and microfluidic (tumor-on-chip) approaches
(193,198). It is evident that ion channels play an oncogenic
role in HGG and additional research in clinically relevant models is required
for the development of effective treatments.
Compelling evidence on the prevalence of ion channel
aberrations in patients with HGG is starting to accumulate. However, while
ion channels are emerging as promising oncogenic targets across many different
cancers, very few ion channel inhibitors have been tested in patients with HGG (177,199).
Clinical failure is largely due to an oversight on the
interaction of ion channels with other oncogenes such as tyrosine kinases and
other ion channel family members. However, these complex interactions may be
key contributors to the cellular and pharmacological response to ion channel
drugs. For example, the same ion channel drug may induce completely different
outcomes in a patient with a kinase mutation as compared to a patient with a
transcription factor mutation. Thus, ion channels need to be studied under
the influence of other oncogenic genes in patients with HGG and
administered as personalized medicine based on the tumor pathology.
Additionally, ion channels compensate for each other’s function (52). This may explain why some drugs can effectively
impede cancer growth while others do not. Hence, it is critical to
study ionic alterations as an orchestra of multiple cellular ion channels
that maintains an electric gradient on the cell membrane to regulate cellular
processes. To achieve this, appropriate in vitro models are necessary (194,200). Testing ion channel drugs in patient
derived HGG neurospheres (201) recapitulates the clinical phenotype and hence, will
significantly increase the success of ion channel drugs
It is important to understand the level of deviation
between the effects of ion channel drugs in
vitro and in vivo compared to the
effects they will have in clinic. Furthermore, it is necessary to undertake
studies in clinically relevant models through multi-omic approaches to better
understand the distinct oncogenic roles of ion channels in HGG. These studies
will enrich our knowledge on the molecular mechanism of ion channel drugs on
HGG tumors and help us understand drug induced resistance. These findings will
facilitate identifying a targeted therapy to treat patients with HGG with
minimal side effects.
Conclusion
The highly plastic, diffusive, and heterogeneous
nature of HGG tumors results in very low patient survival, which has been
improved only minimally with current therapeutic options due to the development
of drug resistance. The current landscape of HGG treatment is characterized by
a combination of surgery, radiotherapy, and chemotherapy, yet these approaches
often fail to extend the patient survival. Ion channels have been identified as
a promising target for HGG therapeutics, due to strong evidence of ion channel
pathologies (abnormalities/mutations) in HGG proliferation, and drug
resistance. The distinct patterns of ion channel expression observed in HGG
compared to normal brain tissues suggest that these channels play a crucial
role in HGG progression. Notably, the upregulation of certain ion channels,
such as those involved in calcium, potassium, and chloride transport,
underscores their potential as biomarkers for HGG prognosis and as targets for
therapeutic intervention. The same ion channels identified as therapeutic
targets could also be used as biomarkers for disease or disease progression.
Ion channel drugs have been repurposed for a host of neurological conditions,
and although these drugs cross the blood-brain barrier, only a few have been
tested for their anti-cancer effects. In addition, their complex mode of action
is not well understood. There is growing evidence of the potential to use ion
channel drugs for cancer therapy, particularly in combination with conventional
therapy, but differences in the pharmacodynamics of ion channel drugs need
further mechanistic investigation. The integration of ion channel-targeting
drugs into clinical protocols offers a promising avenue to enhance therapeutic
efficacy. Preclinical studies have already demonstrated the potential of ion
channel modulators in reducing HGG growth and sensitizing tumors to
conventional treatments. For instance, drugs targeting specific potassium and
chloride channels have shown encouraging results in pre-clinical models by
impairing HGG growth and inducing apoptosis.
Future research should focus on elucidating the
precise roles of various ion channels in HGG pathophysiology and identifying
ion channel-targeting compounds for clinical use. Personalized medicine
approaches, leveraging the unique ion channel expression profiles of individual
tumors, could further refine treatment strategies, ensuring maximal therapeutic
benefit while minimizing adverse effects. New 3D in vitro models using patient-derived cells, tissue engineering and
microfluidic approaches are improving the accurate recapitulation of the tumor
environment and the range and plasticity of cellular states of HGG, showing
promise to elucidate oncogenic mechanisms of HGG. Targeting ion channels
represents a novel and promising therapeutic strategy in the fight against HGG,
with the potential to significantly improve patient outcomes and advance the
current standard of care. Clinically relevant and physiologically accurate
models will improve testing of ion channel drugs, offering a personalized
medicine approach that can be combined with multi-omics to improve our
understanding of HGG, HGG drug resistance and create enhanced therapeutics with
minimal side effects.
Acknowledgment
We
thank the Pirate Ship Foundation, The Cure starts Now, Perth Children’s hospital
Foundation, The Brain Tumor Charity, and the Robert Connor Dawes Foundation for
supporting the research work related to the review. A special thanks to senior
postdoctoral researchers within the institute who mentored us in completing
this review.
Author
contribution
PJM conceptualizing, drafting, editing and
reference collection. NA
conceptualizing and overall editing, CR
drafting and editing.
Conflict
of interest
The
authors report no conflict of interest.
Funding
There
is no funding agency involved in this research.
References
1. Jäkel S,
Dimou L. Glial Cells and Their Function in the Adult Brain: A Journey through
the History of Their Ablation. Front Cell Neurosci. 2017;11:24–24.
2. Zong H,
Verhaak RGW, Canoll P. The cellular origin for malignant glioma and prospects
for clinical advancements. Expert Rev Mol Diagn. 2012 May;12(4):383–94.
3. Forsyth
PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, et al. Gelatinase-A
(MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1
(MT1-MMP) are involved in different aspects of the pathophysiology of malignant
gliomas. Br J Cancer. 1999 Apr;79(11–12):1828–35.
4. Turner KL,
Sontheimer H. Cl- and K+ channels and their role in primary brain tumour
biology. Philos Trans R Soc Lond B Biol Sci. 2014
Mar;369(1638):20130095–20130095.
5. Louis DN,
Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et
al. The 2016 World Health Organization Classification of Tumors of the Central
Nervous System: a summary. Acta Neuropathol (Berl). 2016 Jun;131(6):803–20.
6. Valk PE,
Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol. 1991
Jan;12(1):45–62.
7. Stupp R,
Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of
radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy
alone on survival in glioblastoma in a randomised phase III study: 5-year
analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459–66.
8. Pillay V,
Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, et al. The plasticity
of oncogene addiction: implications for targeted therapies directed to receptor
tyrosine kinases. Neoplasia N Y N. 2009 May;11(5):448–58, 2 p following 458.
9. Mateos-Aparicio
P, Rodríguez-Moreno A. The Impact of Studying Brain Plasticity. Front Cell
Neurosci. 2019;13:66–66.
10. Abou-Antoun
TJ, Hale JS, Lathia JD, Dombrowski SM. Brain Cancer Stem Cells in Adults and
Children: Cell Biology and Therapeutic Implications. Neurother J Am Soc Exp
Neurother. 2017 Apr;14(2):372–84.
11. Simon OJ,
Müntefering T, Grauer OM, Meuth SG. The role of ion channels in malignant brain
tumors. J Neurooncol. 2015 Nov;125(2):225–35.
12. Molenaar
RJ. Ion channels in glioblastoma. ISRN Neurol. 2011;2011:590249–590249.
13. Griffin M,
Khan R, Basu S, Smith S. Ion Channels as Therapeutic Targets in High Grade
Gliomas. Cancers. 2020 Oct;12(10).
14. Kirmiz M,
Palacio S, Thapa P, King AN, Sack JT, Trimmer JS. Remodeling neuronal ER-PM
junctions is a conserved nonconducting function of Kv2 plasma membrane ion
channels. Mol Biol Cell. 2018 Oct;29(20):2410–32.
15. Chittajallu
R, Chen Y, Wang H, Yuan X, Ghiani CA, Heckman T, et al. Regulation of Kv1
subunit expression in oligodendrocyte progenitor cells and their role in G1/S
phase progression of the cell cycle. Proc Natl Acad Sci U S A. 2002
Feb;99(4):2350–5.
16. Ghiani CA,
Yuan X, Eisen AM, Knutson PL, DePinho RA, McBain CJ, et al. Voltage-activated
K+ channels and membrane depolarization regulate accumulation of the
cyclin-dependent kinase inhibitors p27(Kip1) and p21(CIP1) in glial progenitor
cells. J Neurosci Off J Soc Neurosci. 1999 Jul;19(13):5380–92.
17. Becchetti
A. Ion channels and transporters in cancer. 1. Ion channels and cell
proliferation in cancer. Am J Physiol Cell Physiol. 2011 Aug;301(2):C255-65.
18. Bortner CD,
Hughes FM, Cidlowski JA. A primary role for K+ and Na+ efflux in the activation
of apoptosis. J Biol Chem. 1997 Dec;272(51):32436–42.
19. Daoudal G,
Debanne D. Long-term plasticity of intrinsic excitability: learning rules and
mechanisms. Learn Mem Cold Spring Harb N. 2003;10(6):456–65.
20. Naoki H,
Sakumura Y, Ishii S. Local signaling with molecular diffusion as a decoder of
Ca2+ signals in synaptic plasticity. Mol Syst Biol. 2005;1:2005.0027-2005.0027.
21. Dityatev A,
Rusakov DA. Molecular signals of plasticity at the tetrapartite synapse. Curr
Opin Neurobiol. 2011 Apr;21(2):353–9.
22. Zhao X, Han
C, Zeng Z, Liu L, Wang H, Xu J, et al. Glutamate Attenuates the Survival
Property of IGFR through NR2B Containing N-Methyl-D-aspartate Receptors in
Cortical Neurons. Oxid Med Cell Longev. 2020;2020:5173184–5173184.
23. Ryland KE,
Hawkins AG, Weisenberger DJ, Punj V, Borinstein SC, Laird PW, et al. Promoter
Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing
Sarcoma Cell Proliferation. Mol Cancer Res MCR. 2016 Jan;14(1):26–34.
24. Liu ZB, Liu
C, Zeng B, Huang LP, Yao LH. Modulation Effects of Cordycepin on Voltage-Gated
Sodium Channels in Rat Hippocampal CA1 Pyramidal Neurons in the
Presence/Absence of Oxygen. Neural Plast. 2017;2017:2459053–2459053.
25. HODGKIN AL,
HUXLEY AF. A quantitative description of membrane current and its application
to conduction and excitation in nerve. J Physiol. 1952 Aug;117(4):500–44.
26. Catacuzzeno
L, Sforna L, Esposito V, Limatola C, Franciolini F. Ion Channels in Glioma
Malignancy. Rev Physiol Biochem Pharmacol. 2021;181:223–67.
27. Liu J, Qu
C, Han C, Chen MM, An LJ, Zou W. Potassium channels and their role in glioma: A
mini review. Mol Membr Biol. 2019 Dec;35(1):76–85.
28. Varricchio
A, Ramesh SA, Yool AJ. Novel Ion Channel Targets and Drug Delivery Tools for
Controlling Glioblastoma Cell Invasiveness. Int J Mol Sci. 2021 Nov;22(21).
29. Parsons DW,
Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An integrated genomic
analysis of human glioblastoma multiforme. Science. 2008 Sep;321(5897):1807–12.
30. Joshi AD,
Parsons DW, Velculescu VE, Riggins GJ. Sodium ion channel mutations in
glioblastoma patients correlate with shorter survival. Mol Cancer. 2011
Feb;10:17–17.
31. Sheykhzadeh
S, Luo M, Peng B, White J, Abdalla Y, Tang T, et al. Transferrin-targeted
porous silicon nanoparticles reduce glioblastoma cell migration across tight
extracellular space. Sci Rep. 2020 Feb;10(1):2320–2320.
32. Olsen ML,
Weaver AK, Ritch PS, Sontheimer H. Modulation of glioma BK channels via erbB2.
J Neurosci Res. 2005 Jul;81(2):179–89.
33. Abbott NJ,
Khan EU, Rollinson CMS, Reichel A, Janigro D, Dombrowski SM, et al. Drug
resistance in epilepsy: the role of the blood-brain barrier. Novartis Found
Symp. 2002;243:38–5.
34. Elias AF,
Lin BC, Piggott BJ. Ion Channels in Gliomas-From Molecular Basis to Treatment.
Int J Mol Sci. 2023 Jan;24(3).
35. Keluth S,
Jitte S, Bhushan R, Ranjan OP, Murti K, Ravichandiran V, et al. Targeting Ion
Channels for the Treatment of Glioma. Mini-Rev Med Chem. 2023
Jul;23(12):1298–318.
36. Kirtonia A,
Gala K, Fernandes SG, Pandya G, Pandey AK, Sethi G, et al. Repurposing of
drugs: An attractive pharmacological strategy for cancer therapeutics. Semin
Cancer Biol. 2021 Jan;68:258–78.
37. Gadsby DC.
Ion channels versus ion pumps: the principal difference, in principle. Nat Rev
Mol Cell Biol. 2009 May;10(5):344–52.
38. Anderson
KJ, Cormier RT, Scott PM. Role of ion channels in gastrointestinal cancer.
World J Gastroenterol. 2019 Oct;25(38):5732–72.
39. Green WN.
Ion channel assembly: creating structures that function. J Gen Physiol. 1999
Feb;113(2):163–70.
40. Unwin N.
The structure of ion channels in membranes of excitable cells. Neuron. 1989
Dec;3(6):665–76.
41. Isacoff EY,
Jan LY, Minor DL. Conduits of life’s spark: a perspective on ion channel
research since the birth of neuron. Neuron. 2013 Oct;80(3):658–74.
42. Kulbacka J,
Choromańska A, Rossowska J, Weżgowiec J, Saczko J, Rols MP. Cell Membrane
Transport Mechanisms: Ion Channels and Electrical Properties of Cell Membranes.
Adv Anat Embryol Cell Biol. 2017;227:39–58.
43. Fohlmeister
JF. Voltage gating by molecular subunits of Na+ and K+ ion channels:
higher-dimensional cubic kinetics, rate constants, and temperature. J
Neurophysiol. 2015 Jun;113(10):3759–77.
44. Abdul Kadir
L, Stacey M, Barrett-Jolley R. Emerging Roles of the Membrane Potential: Action
Beyond the Action Potential. Front Physiol. 2018;9:1661–1661.
45. Shah S, Chu
Y, Cegielski V, Chu XP. Acid-Sensing Ion Channel 1 Contributes to Weak
Acid-Induced Migration of Human Malignant Glioma Cells. Front Physiol.
2021;12:734418–734418.
46. Armstrong
CM. Na channel inactivation from open and closed states. Proc Natl Acad Sci.
2006 Nov;103(47):17991–6.
47. Waszkielewicz
AM, Gunia A, Szkaradek N, Słoczyńska K, Krupińska S, Marona H. Ion channels as
drug targets in central nervous system disorders. Curr Med Chem.
2013;20(10):1241–85.
48. Nelson MT,
Todorovic SM, Perez-Reyes E. The role of T-type calcium channels in epilepsy
and pain. Curr Pharm Des. 2006;12(18):2189–97.
49. Smart TG,
Paoletti P. Synaptic neurotransmitter-gated receptors. Cold Spring Harb
Perspect Biol. 2012 Mar;4(3).
50. Cheng KT,
Ong HL, Liu X, Ambudkar IS. Contribution and regulation of TRPC channels in
store-operated Ca2+ entry. Curr Top Membr. 2013;71:149–79.
51. Catterall
WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011
Aug;3(8):a003947–a003947.
52. Rosati B,
McKinnon D. Regulation of ion channel expression. Circ Res. 2004
Apr;94(7):874–83.
53. Soriani O,
Rapetti-Mauss R. Sigma 1 Receptor and Ion Channel Dynamics in Cancer. Adv Exp
Med Biol. 2017;964:63–77.
54. Haworth AS,
Brackenbury WJ. Emerging roles for multifunctional ion channel auxiliary
subunits in cancer. Cell Calcium. 2019 Jun;80:125–40.
55. Capatina
AL, Lagos D, Brackenbury WJ. Targeting Ion Channels for Cancer Treatment:
Current Progress and Future Challenges. Rev Physiol Biochem Pharmacol.
2022;183:1–43.
56. Litan A,
Langhans SA. Cancer as a channelopathy: ion channels and pumps in tumor
development and progression. Front Cell Neurosci. 2015;9:86–86.
57. Pedersen
SF, Stock C. Ion channels and transporters in cancer: pathophysiology,
regulation, and clinical potential. Cancer Res. 2013 Mar;73(6):1658–61.
58. Farfariello
V, Prevarskaya N, Gkika D. Ion Channel Profiling in Prostate Cancer: Toward
Cell Population-Specific Screening. Rev Physiol Biochem Pharmacol.
2021;181:39–56.
59. Prevarskaya
N, Skryma R, Shuba Y. Ion Channels in Cancer: Are Cancer Hallmarks
Oncochannelopathies? Physiol Rev. 2018 Apr;98(2):559–621.
60. Shuttleworth
TJ. Intracellular Ca2+ signalling in secretory cells. J Exp Biol. 1997
Jan;200(Pt 2):303–14.
61. Rizzuto R,
De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators
of calcium signalling. Nat Rev Mol Cell Biol. 2012 Sep;13(9):566–78.
62. Kondratskyi
A, Yassine M, Kondratska K, Skryma R, Slomianny C, Prevarskaya N.
Calcium-permeable ion channels in control of autophagy and cancer. Front
Physiol. 2013;4:272–272.
63. Braun M,
Ramracheya R, Bengtsson M, Zhang Q, Karanauskaite J, Partridge C, et al.
Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological
characterization and role in insulin secretion. Diabetes. 2008
Jun;57(6):1618–28.
64. Roux B. Ion
channels and ion selectivity. Essays Biochem. 2017 May;61(2):201–9.
65. Talvenheimo
JA. The purification of ion channels from excitable cells. J Membr Biol.
1985;87(2):77–91.
66. Gusovsky F,
Daly JW. Formation of second messengers in response to activation of ion
channels in excitable cells. Cell Mol Neurobiol. 1988 Jun;8(2):157–69.
67. Bertrán GC,
D’Alessio C, Kotsias BA. [Ion channels in non excitable cells]. Medicina (Mex).
1995;55(5 Pt 1):449–56.
68. Kramer RH,
Chambers JJ, Trauner D. Photochemical tools for remote control of ion channels
in excitable cells. Nat Chem Biol. 2005 Dec;1(7):360–5.
69. Deng XL,
Lau CP, Lai K, Cheung KF, Lau GK, Li GR. Cell cycle-dependent expression of
potassium channels and cell proliferation in rat mesenchymal stem cells from
bone marrow. Cell Prolif. 2007 Oct;40(5):656–70.
70. Urrego D,
Tomczak AP, Zahed F, Stühmer W, Pardo LA. Potassium channels in cell cycle and
cell proliferation. Philos Trans R Soc Lond B Biol Sci. 2014
Mar;369(1638):20130094–20130094.
71. Ekhterae D,
Platoshyn O, Krick S, Yu Y, McDaniel SS, Yuan JX. Bcl-2 decreases voltage-gated
K+ channel activity and enhances survival in vascular smooth muscle cells. Am J
Physiol Cell Physiol. 2001 Jul;281(1):C157-65.
72. Williams
SS, French JN, Gilbert M, Rangaswami AA, Walleczek J, Knox SJ. Bcl-2
overexpression results in enhanced capacitative calcium entry and resistance to
SKF-96365-induced apoptosis. Cancer Res. 2000 Aug;60(16):4358–61.
73. Roden DM,
Kupershmidt S. From genes to channels: normal mechanisms. Cardiovasc Res. 1999
May;42(2):318–26.
74. Wickenden
A, Priest B, Erdemli G. Ion channel drug discovery: challenges and future
directions. Future Med Chem. 2012 Apr;4(5):661–79.
75. Chen H,
Ikeda SR. Modulation of ion channels and synaptic transmission by a human
sensory neuron-specific G-protein-coupled receptor, SNSR4/mrgX1, heterologously
expressed in cultured rat neurons. J Neurosci Off J Soc Neurosci. 2004
May;24(21):5044–53.
76. Anderson
AJ, Harvey AL. Effects of the potassium channel blocking dendrotoxins on
acetylcholine release and motor nerve terminal activity. Br J Pharmacol. 1988
Jan;93(1):215–21.
77. Ge L, Hoa
NT, Wilson Z, Arismendi-Morillo G, Kong XT, Tajhya RB, et al. Big Potassium
(BK) ion channels in biology, disease and possible targets for cancer
immunotherapy. Int Immunopharmacol. 2014 Oct;22(2):427–43.
78. Leanza L,
Biasutto L, Managò A, Gulbins E, Zoratti M, Szabò I. Intracellular ion channels
and cancer. Front Physiol. 2013 Sep;4:227–227.
79. Peruzzo R,
Biasutto L, Szabò I, Leanza L. Impact of intracellular ion channels on cancer
development and progression. Eur Biophys J EBJ. 2016 Oct;45(7):685–707.
80. Lev S,
Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, et al. Protein tyrosine
kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase
functions. Nature. 1995 Aug;376(6543):737–45.
81. Cheng W,
Zhu Y, Wang H. The MAPK pathway is involved in the regulation of rapid
pacing-induced ionic channel remodeling in rat atrial myocytes. Mol Med Rep.
2016 Mar;13(3):2677–82.
82. Melnikova
IN, Gardner PD. The signal transduction pathway underlying ion channel gene
regulation by SP1-C-Jun interactions. J Biol Chem. 2001 Jun;276(22):19040–5.
83. Bahcheli
AT, Min HK, Bayati M, Zhao H, Fortuna A, Dong W, et al. Pan-cancer ion
transport signature reveals functional regulators of glioblastoma aggression.
EMBO J. 2024 Jan;43(2):196–224.
84. Hoffmann
EK, Lambert IH. Ion channels and transporters in the development of drug
resistance in cancer cells. Philos Trans R Soc Lond B Biol Sci. 2014
Mar;369(1638):20130109–20130109.
85. Szado T,
Vanderheyden V, Parys JB, De Smedt H, Rietdorf K, Kotelevets L, et al.
Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase
B/Akt inhibits Ca2+ release and apoptosis. Proc Natl Acad Sci U S A. 2008
Feb;105(7):2427–32.
86. Liu H,
Hughes JD, Rollins S, Chen B, Perkins E. Calcium entry via ORAI1 regulates
glioblastoma cell proliferation and apoptosis. Exp Mol Pathol. 2011
Dec;91(3):753–60.
87. McFerrin
MB, Turner KL, Cuddapah VA, Sontheimer H. Differential role of IK and BK
potassium channels as mediators of intrinsic and extrinsic apoptotic cell
death. Am J Physiol Cell Physiol. 2012 Nov;303(10):C1070-8.
88. Ransom CB,
Sontheimer H. BK channels in human glioma cells. J Neurophysiol. 2001
Feb;85(2):790–803.
89. Ransom CB,
Liu X, Sontheimer H. BK channels in human glioma cells have enhanced calcium
sensitivity. Glia. 2002 Jun;38(4):281–91.
90. Liu X,
Chang Y, Reinhart PH, Sontheimer H, Chang Y. Cloning and characterization of
glioma BK, a novel BK channel isoform highly expressed in human glioma cells. J
Neurosci Off J Soc Neurosci. 2002 Mar;22(5):1840–9.
91. Olsen ML,
Schade S, Lyons SA, Amaral MD, Sontheimer H. Expression of voltage-gated
chloride channels in human glioma cells. J Neurosci Off J Soc Neurosci. 2003
Jul;23(13):5572–82.
92. Sontheimer
H. Ion channels and amino acid transporters support the growth and invasion of
primary brain tumors. Mol Neurobiol. 2004 Feb;29(1):61–71.
93. McFerrin
MB, Sontheimer H. A role for ion channels in glioma cell invasion. Neuron Glia
Biol. 2006 Feb;2(1):39–49.
94. Ruggieri P,
Mangino G, Fioretti B, Catacuzzeno L, Puca R, Ponti D, et al. The inhibition of
KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer
stem cells. PloS One. 2012;7(10):e47825–e47825.
95. Huber SM,
Butz L, Stegen B, Klumpp L, Klumpp D, Eckert F. Role of ion channels in
ionizing radiation-induced cell death. Biochim Biophys Acta. 2015 Oct;1848(10
Pt B):2657–64.
96. Habela CW,
Olsen ML, Sontheimer H. ClC3 is a critical regulator of the cell cycle in
normal and malignant glial cells. J Neurosci Off J Soc Neurosci. 2008
Sep;28(37):9205–17.
97. Turner KL,
Honasoge A, Robert SM, McFerrin MM, Sontheimer H. A proinvasive role for the
Ca(2+) -activated K(+) channel KCa3.1 in malignant glioma. Glia. 2014
Jun;62(6):971–81.
98. Barbieri F,
Verduci I, Carlini V, Zona G, Pagano A, Mazzanti M, et al. Repurposed Biguanide
Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of
Intracellular Chloride Channel 1 Activity. Front Oncol. 2019;9:135–135.
99. García-Santisteban
I, Peters GJ, Giovannetti E, Rodríguez JA. USP1 deubiquitinase: cellular
functions, regulatory mechanisms and emerging potential as target in cancer
therapy. Mol Cancer. 2013 Aug;12:91–91.
100. Ranjan A,
Srivastava SK. Penfluridol suppresses glioblastoma tumor growth by Akt-mediated
inhibition of GLI1. Oncotarget. 2017 May;8(20):32960–76.
101. Pollak J,
Rai KG, Funk CC, Arora S, Lee E, Zhu J, et al. Ion channel expression patterns
in glioblastoma stem cells with functional and therapeutic implications for
malignancy. PloS One. 2017;12(3):e0172884–e0172884.
102. Madhavan S,
Zenklusen JC, Kotliarov Y, Sahni H, Fine HA, Buetow K. Rembrandt: helping
personalized medicine become a reality through integrative translational
research. Mol Cancer Res MCR. 2009 Feb;7(2):157–67.
103. Zhang Y,
Zhang J, Jiang D, Zhang D, Qian Z, Liu C, et al. Inhibition of T-type Ca2+
channels by endostatin attenuates human glioblastoma cell proliferation and
migration. Br J Pharmacol. 2012 Jun;166(4):1247–60.
104. Zhang Y,
Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, et al. Targetable
T-type Calcium Channels Drive Glioblastoma. Cancer Res. 2017
Jul;77(13):3479–90.
105. Cheng YR,
Jiang BY, Chen CC. Acid-sensing ion channels: dual function proteins for
chemo-sensing and mechano-sensing. J Biomed Sci. 2018 May;25(1):46–46.
106. Sivils A,
Yang F, Wang JQ, Chu XP. Acid-Sensing Ion Channel 2: Function and Modulation.
Membranes. 2022 Jan;12(2).
107. Berdiev BK,
Xia J, McLean LA, Markert JM, Gillespie GY, Mapstone TB, et al. Acid-sensing
ion channels in malignant gliomas. J Biol Chem. 2003 Apr;278(17):15023–34.
108. Tian Y,
Bresenitz P, Reska A, El Moussaoui L, Beier CP, Gründer S. Glioblastoma cancer
stem cell lines express functional acid sensing ion channels ASIC1a and ASIC3.
Sci Rep. 2017 Oct;7(1):13674–13674.
109. Caldwell JH,
Schaller KL, Lasher RS, Peles E, Levinson SR. Sodium channel Nav1. 6 is
localized at nodes of Ranvier, dendrites, and synapses. Proc Natl Acad Sci.
2000;97(10):5616–20.
110. Ai Y, Zhang
X, Hu X, Gao J, Liu J, Ou S, et al. Role of the voltage‑gated sodium channel
Nav1.6 in glioma and candidate drugs screening. Int J Mol Med. 2023 Jun;51(6).
111. Boyle Y,
Johns TG, Fletcher EV. Potassium Ion Channels in Malignant Central Nervous
System Cancers. Cancers. 2022 Sep;14(19).
112. Berkefeld H,
Sailer CA, Bildl W, Rohde V, Thumfart JO, Eble S, et al. BKCa-Cav channel
complexes mediate rapid and localized Ca2+-activated K+ signaling. Science.
2006 Oct;314(5799):615–20.
113. Comes N,
Bielanska J, Vallejo-Gracia A, Serrano-Albarrás A, Marruecos L, Gómez D, et al.
The voltage-dependent K+ channels Kv1. 3 and Kv1. 5 in human cancer. Front
Physiol. 2013;4:283.
114. Bielanska J,
Hernandez-Losa J, Perez-Verdaguer M, Moline T, Somoza R, Cajal S, et al.
Voltage-dependent potassium channels Kv1. 3 and Kv1. 5 in human cancer. Curr
Cancer Drug Targets. 2009;9(8):904–14.
115. Arvind S,
Arivazhagan A, Santosh V, Chandramouli BA. Differential expression of a novel
voltage gated potassium channel--Kv 1.5 in astrocytomas and its impact on
prognosis in glioblastoma. Br J Neurosurg. 2012 Feb;26(1):16–20.
116. Meizeng L,
Tian P, Qing Zhao, Xialin Ma, Yunxiang Zhang, Li. Potassium channels: Novel
targets for tumor diagnosis and chemoresistance. Front Oncol.
2023;(12):1074469.
117. Ohno Y,
Kunisawa N, Shimizu S. Emerging roles of astrocyte Kir4. 1 channels in the
pathogenesis and treatment of brain diseases. Int J Mol Sci. 2021;22(19):10236.
118. Higashimori
H, Sontheimer H. Role of Kir4.1 channels in growth control of glia. Glia. 2007
Dec;55(16):1668–79.
119. Franciolini
F, Petris A. Chloride channels of biological membranes. Biochim Biophys Acta
BBA-Rev Biomembr. 1990;1031(2):247–59.
120. Nilius B,
Droogmans G. Amazing chloride channels: an overview. Acta Physiol Scand.
2003;177(2):119–47.
121. Wang CY, Lai
MD, Phan NN, Sun Z, Lin YC. Meta-Analysis of Public Microarray Datasets Reveals
Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients. PloS One.
2015;10(7):e0125766–e0125766.
122. Griffin M,
Basu S, Khan R, Smith S. CLIC1 and CLIC4 Ion Channel Deficiency Confers
Increased Sensitivity to Tumour Treating Fields and Improved Survival in
Paediatric Glioblastoma. Neuro-Oncol. 2022 Oct;24(Supplement_4):iv4–iv4.
123. Sciaccaluga
M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, Rosito M, et al.
CXCL12-induced glioblastoma cell migration requires intermediate conductance
Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol. 2010
Jul;299(1):C175-84.
124. Cuddapah VA,
Sontheimer H. Molecular interaction and functional regulation of ClC-3 by
Ca2+/calmodulin-dependent protein kinase II (CaMKII) in human malignant glioma.
J Biol Chem. 2010;285(15):11188–96.
125. Sun P, Mu Y,
Zhang S. A novel NF-κB/MMP-3 signal pathway involves in the aggressivity of
glioma promoted by Bmi-1. Tumor Biol. 2014;35:12721–7.
126. Wang B, Xie
J, He HY, Huang EW, Cao QH, Luo L, et al. Suppression of CLC-3 chloride channel
reduces the aggressiveness of glioma through inhibiting nuclear factor-κB
pathway. Oncotarget. 2017;8(38):63788.
127. Sontheimer
H. An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med
Maywood NJ. 2008 Jul;233(7):779–91.
128. Ernest NJ,
Weaver AK, Van Duyn LB, Sontheimer HW. Relative contribution of chloride
channels and transporters to regulatory volume decrease in human glioma cells.
Am J Physiol-Cell Physiol. 2005;288(6):C1451–60.
129. Chinigò G,
Castel H, Chever O, Gkika D. TRP Channels in Brain Tumors. Front Cell Dev Biol.
2021;9:617801–617801.
130. Alptekin M,
Eroglu S, Tutar E, Sencan S, Geyik MA, Ulasli M, et al. Gene expressions of TRP
channels in glioblastoma multiforme and relation with survival. Tumour Biol J
Int Soc Oncodevelopmental Biol Med. 2015 Dec;36(12):9209–13.
131. Gehring MP,
Kipper F, Nicoletti NF, Sperotto ND, Zanin R, Tamajusuku ASK, et al. P2X7
receptor as predictor gene for glioma radiosensitivity and median survival. Int
J Biochem Cell Biol. 2015 Nov;68:92–100.
132. Chen X,
Momin A, Wanggou S, Wang X, Min HK, Dou W, et al. Mechanosensitive brain tumor
cells construct blood-tumor barrier to mask chemosensitivity. Neuron. 2023
Jan;111(1):30-48.e14.
133. Qu S, Hu T,
Qiu O, Su Y, Gu J, Xia Z. Effect of Piezo1 Overexpression on Peritumoral Brain
Edema in Glioblastomas. AJNR Am J Neuroradiol. 2020 Aug;41(8):1423–9.
134. Goldman DE.
Potential, impedance, and rectification in membranes. J Gen Physiol.
1943;27(1):37–60.
135. Levin M.
Large-scale biophysics: ion flows and regeneration. Trends Cell Biol.
2007;17(6):261–70.
136. Hodgkin AL,
Katz B. The effect of sodium ions on the electrical activity of the giant axon
of the squid. J Physiol. 1949;108(1):37.
137. Imbrici P,
Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, et al. Therapeutic
Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.
Front Pharmacol. 2016;7:121–121.
138. Markman JD,
Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. J
Pain. 2006 Jan;7(1 Suppl 1):S38-47.
139. Grigoriadis
DE, Hoare SRJ, Lechner SM, Slee DH, Williams JA. Drugability of extracellular
targets: discovery of small molecule drugs targeting allosteric, functional,
and subunit-selective sites on GPCRs and ion channels. Neuropsychopharmacol Off
Publ Am Coll Neuropsychopharmacol. 2009 Jan;34(1):106–25.
140. Caban A,
Pisarczyk K, Kopacz K, Kapuśniak A, Toumi M, Rémuzat C, et al. Filling the gap
in CNS drug development: evaluation of the role of drug repurposing. J Mark
Access Health Policy. 2017;5(1):1299833.
141. McManus OB,
Garcia ML, Weaver D, Bryant M, Titus S, Herrington JB. Ion Channel Screening,
in Assay Guidance Manual. 2012.
142. Gubič Š,
Hendrickx LA, Toplak Ž, Sterle M, Peigneur S, Tomašič T, et al. Discovery of KV
1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges. Med
Res Rev. 2021 Jul;41(4):2423–73.
143. Yu H bo, Li
M, Wang W ping, Wang X liang. High throughput screening technologies for ion
channels. Acta Pharmacol Sin. 2016 Jan;37(1):34–43.
144. Kwok TCY,
Ricker N, Fraser R, Chan AW, Burns A, Stanley EF, et al. A small-molecule
screen in C. elegans yields a new calcium channel antagonist. Nature. 2006
May;441(7089):91–5.
145. Burns AR,
Wallace IM, Wildenhain J, Tyers M, Giaever G, Bader GD, et al. A predictive
model for drug bioaccumulation and bioactivity in Caenorhabditis elegans. Nat
Chem Biol. 2010 Jul;6(7):549–57.
146. Jiang Q, Li
K, Lu WJ, Li S, Chen X, Liu XJ, et al. Identification of small-molecule ion
channel modulators in C. elegans channelopathy models. Nat Commun. 2018
Sep;9(1):3941–3941.
147. Clare JJ.
Targeting ion channels for drug discovery. Discov Med. 2010 Mar;9(46):253–60.
148. Hammarstrom
AK, Gage PW. Inhibition of oxidative metabolism increases persistent sodium
current in rat CA1 hippocampal neurons. J Physiol. 1998 Aug;510 ( Pt 3)(Pt
3):735–41.
149. Issa FA,
Mock AF, Sagasti A, Papazian DM. Spinocerebellar ataxia type 13 mutation that
is associated with disease onset in infancy disrupts axonal pathfinding during
neuronal development. Dis Model Mech. 2012 Nov;5(6):921–9.
150. Cooper EC,
Jan LY. Ion channel genes and human neurological disease: recent progress,
prospects, and challenges. Proc Natl Acad Sci U S A. 1999 Apr;96(9):4759–66.
151. Lipkind GM,
Fozzard HA. Molecular model of anticonvulsant drug binding to the voltage-gated
sodium channel inner pore. Mol Pharmacol. 2010 Oct;78(4):631–8.
152. Mycielska
ME, Palmer CP, Brackenbury WJ, Djamgoz MB. Expression of Na+‐dependent citrate
transport in a strongly metastatic human prostate cancer PC‐3M cell line:
regulation by voltage‐gated Na+ channel activity. J Physiol.
2005;563(2):393–408.
153. Cameron IL,
Smith NK, Pool T, Sparks R. Intracellular concentration of sodium and other
elements as related to mitogenesis and oncogenesis in vivo. Cancer Res.
1980;40(5):1493–500.
154. Yang M,
Kozminski DJ, Wold LA, Modak R, Calhoun JD, Isom LL, et al. Therapeutic
potential for phenytoin: Targeting Na v 1.5 sodium channels to reduce migration
and invasion in metastatic breast cancer. Breast Cancer Res Treat.
2012;134:603–15.
155. Szabo I,
Zoratti M, Biasutto L. Targeting mitochondrial ion channels for cancer therapy.
Redox Biol. 2021 Jun;42:101846–101846.
156. Yang J, Yu
G, Sessler JL, Shin I, Gale PA, Huang F. Artificial transmembrane ion
transporters as potential therapeutics. Chem. 2021 Dec;7(12):3256–91.
157. Prevarskaya
N, Skryma R, Shuba Y. Ion channels and the hallmarks of cancer. Trends Mol Med.
2010;16(3):107–21.
158. Arcangeli A,
Becchetti A. Integrin structure and functional relation with ion channels.
Integrins Ion Channels Mol Complexes Signal. 2010;1–7.
159. Djamgoz MB,
Mycielska M, Madeja Z, Fraser SP, Korohoda W. Directional movement of rat
prostate cancer cells in direct-current electric field: involvement of
voltagegated Na+ channel activity. J Cell Sci. 2001;114(14):2697–705.
160. K K. Ion
channels and cancer. J Membr Biol. 2005;(205):159–73.
161. Lang F,
Stournaras C. Ion channels in cancer: future perspectives and clinical
potential. Philos Trans R Soc Lond B Biol Sci. 2014
Mar;369(1638):20130108–20130108.
162. Dai X, Wang
D, Zhang J. Programmed cell death, redox imbalance, and cancer therapeutics.
Apoptosis Int J Program Cell Death. 2021 Aug;26(7–8):385–414.
163. Azimi I,
Robitaille M, Armitage K, So CL, Milevskiy MJG, Northwood K, et al. Activation
of the Ion Channel TRPV4 Induces Epithelial to Mesenchymal Transition in Breast
Cancer Cells. Int J Mol Sci. 2020 Dec;21(24).
164. Nelson M,
Yang M, Dowle AA, Thomas JR, Brackenbury WJ. The sodium channel-blocking
antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Mol
Cancer. 2015 Jan;14(1):13–13.
165. Jahchan NS,
Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, et al. A drug repositioning
approach identifies tricyclic antidepressants as inhibitors of small cell lung
cancer and other neuroendocrine tumors. Cancer Discov. 2013 Dec;3(12):1364–77.
166. Millward MJ,
Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Oral verapamil with
chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J
Cancer. 1993 May;67(5):1031–5.
167. Dalton WS,
Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, et al. A phase III
randomized study of oral verapamil as a chemosensitizer to reverse drug
resistance in patients with refractory myeloma. A Southwest Oncology Group
study. Cancer. 1995 Feb;75(3):815–20.
168. Sarkaria JN,
Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of
chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res Off J
Am Assoc Cancer Res. 2008 May;14(10):2900–8.
169. Friedman HS,
McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair
and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in
newly diagnosed malignant glioma. J Clin Oncol Off J Am Soc Clin Oncol. 1998
Dec;16(12):3851–7.
170. Simonetti G,
Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A. Clinical management
of grade III oligodendroglioma. Cancer Manag Res. 2015;7:213–23.
171. Jamal M,
Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment
preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like
cells. Neoplasia N Y N. 2012 Feb;14(2):150–8.
172. Blaney SM,
Poplack DG. Pharmacologic strategies for the treatment of meningeal malignancy.
Invest New Drugs. 1996;14:69–85.
173. Rominiyi O,
Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ. Tumour
treating fields therapy for glioblastoma: current advances and future
directions. Br J Cancer. 2021;124(4):697–709.
174. Varricchio
A, Yool AJ. Aquaporins and Ion Channels as Dual Targets in the Design of Novel
Glioblastoma Therapeutics to Limit Invasiveness. Cancers. 2023 Jan;15(3).
175. Xu B, Mao J,
Wang L, Zhu L, Li H, Wang W, et al. ClC-3 chloride channels are essential for
cell proliferation and cell cycle progression in nasopharyngeal carcinoma
cells. Acta Biochim Biophys Sin. 2010 Jun;42(6):370–80.
176. Kasai T,
Nakamura K, Vaidyanath A, Chen L, Sekhar S, El-Ghlban S, et al. Chlorotoxin
Fused to IgG-Fc Inhibits Glioblastoma Cell Motility via Receptor-Mediated
Endocytosis. J Drug Deliv. 2012;2012:975763–975763.
177. Mamelak AN,
Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other
malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007
Mar;4(2):175–86.
178. Hockaday DC,
Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, et al. Imaging glioma
extent with 131I-TM-601. J Nucl Med Off Publ Soc Nucl Med. 2005
Apr;46(4):580–6.
179. Lyons SA,
O’Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically
binds to gliomas and tumors of neuroectodermal origin. Glia. 2002
Aug;39(2):162–73.
180. Setti M,
Savalli N, Osti D, Richichi C, Angelini M, Brescia P, et al. Functional role of
CLIC1 ion channel in glioblastoma-derived stem/progenitor cells. J Natl Cancer
Inst. 2013 Nov;105(21):1644–55.
181. Bayat
Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al.
Combination therapy in combating cancer. Oncotarget. 2017 Jun;8(23):38022–43.
182. Mathews J,
Kuchling F, Baez-Nieto D, Diberardinis M, Pan JQ, Levin M. Ion Channel Drugs
Suppress Cancer Phenotype in NG108-15 and U87 Cells: Toward Novel
Electroceuticals for Glioblastoma. Cancers. 2022 Mar;14(6).
183. Su VYF, Hu
YW, Chou KT, Ou SM, Lee YC, Lin EYH, et al. Amiodarone and the risk of cancer:
a nationwide population-based study. Cancer. 2013 May;119(9):1699–705.
184. Kim BJ, Kim
SY, Lee S, Jeon JH, Matsui H, Kwon YK, et al. The role of transient receptor
potential channel blockers in human gastric cancer cell viability. Can J
Physiol Pharmacol. 2012 Feb;90(2):175–86.
185. Kim IY, Kang
YJ, Yoon MJ, Kim EH, Kim SU, Kwon TK, et al. Amiodarone sensitizes human glioma
cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5
upregulation. Neuro-Oncol. 2011 Mar;13(3):267–79.
186. Rath BH,
Camphausen K, Tofilon PJ. Glioblastoma radiosensitization by pimozide. Transl
Cancer Res. 2016 Nov;5(Suppl 6):S1029–32.
187. Kondo S, Yin
D, Morimura T, Kubo H, Nakatsu S, Takeuchi J. Combination therapy with
cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and
cisplatin-resistant human glioblastoma cells. Br J Cancer. 1995
Feb;71(2):282–9.
188. Krouse AJ,
Gray L, Macdonald T, McCray J. Repurposing and Rescuing of Mibefradil, an
Antihypertensive, for Cancer: A Case Study. Assay Drug Dev Technol. 2015
Dec;13(10):650–3.
189. Holdhoff M,
Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, et al. Timed sequential therapy
of the selective T-type calcium channel blocker mibefradil and temozolomide in
patients with recurrent high-grade gliomas. Neuro-Oncol. 2017 Jun;19(6):845–52.
190. Keir ST,
Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for
glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a
murine model. J Neurooncol. 2013 Jan;111(2):97–102.
191. Mullins ME,
Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J. Life-threatening
interaction of mibefradil and beta-blockers with dihydropyridine calcium
channel blockers. JAMA. 1998 Jul;280(2):157–8.
192. Papin JA,
Hunter T, Palsson BO, Subramaniam S. Reconstruction of cellular signalling
networks and analysis of their properties. Nat Rev Mol Cell Biol. 2005
Feb;6(2):99–111.
193. Higginbottom
SL, Tomaskovic-Crook E, Crook JM. Considerations for modelling diffuse
high-grade gliomas and developing clinically relevant therapies. Cancer
Metastasis Rev. 2023;42(2):507–41.
194. Zottel A,
Jovčevska I, Šamec N. Non-animal glioblastoma models for personalized
treatment. Heliyon. 2023;
195. Ahmed T.
Biomaterial-based in vitro 3D modeling of glioblastoma multiforme. Cancer
Pathog Ther. 2023;1(03):177–94.
196. Fan Y,
Nguyen DT, Akay Y, Xu F, Akay M. Engineering a brain cancer chip for
high-throughput drug screening. Sci Rep. 2016;6(1):25062.
197. Thenuwara G,
Javed B, Singh B, Tian F. Biosensor-Enhanced Organ-on-a-Chip Models for
Investigating Glioblastoma Tumor Microenvironment Dynamics. Sensors.
2024;24(9):2865.
198. Maffeo C,
Bhattacharya S, Yoo J, Wells D, Aksimentiev A. Modeling and simulation of ion
channels. Chem Rev. 2012;112(12):6250–84.
199. Mamelak AN,
Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, et al. Phase I
single-dose study of intracavitary-administered iodine-131-TM-601 in adults
with recurrent high-grade glioma. J Clin Oncol Off J Am Soc Clin Oncol. 2006
Aug;24(22):3644–50.
200. FOLGIERO V,
ROMANIA P, ROSSI F, CAFORIO M, NIC M, DIBUSZ K, et al. Advanced Non-animal
Models in Biomedical Research. 2020;
201. Stringer BW,
Day BW, D’Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, et al. A reference
collection of patient-derived cell line and xenograft models of proneural,
classical and mesenchymal glioblastoma. Sci Rep. 2019 Mar;9(1):4902–4902.
202. Chen JP,
Luan Y, You CX, Chen XH, Luo RC, Li R. TRPM7 regulates the migration of human
nasopharyngeal carcinoma cell by mediating Ca(2+) influx. Cell Calcium. 2010
May;47(5):425–32.
203. Ding X, He
Z, Shi Y, Wang Q, Wang Y. Targeting TRPC6 channels in oesophageal carcinoma
growth. Expert Opin Ther Targets. 2010 May;14(5):513–27.
204. Shiozaki A,
Kudou M, Ichikawa D, Fujiwara H, Shimizu H, Ishimoto T, et al. Esophageal
cancer stem cells are suppressed by tranilast, a TRPV2 channel inhibitor. J
Gastroenterol. 2018 Feb;53(2):197–207.
205. Choi S, Cui
C, Luo Y, Kim SH, Ko JK, Huo X, et al. Selective inhibitory effects of zinc on
cell proliferation in esophageal squamous cell carcinoma through Orai1. FASEB J
Off Publ Fed Am Soc Exp Biol. 2018 Jan;32(1):404–16.
206. Asghar MY,
Magnusson M, Kemppainen K, Sukumaran P, Löf C, Pulli I, et al. Transient
Receptor Potential Canonical 1 (TRPC1) Channels as Regulators of Sphingolipid
and VEGF Receptor Expression: IMPLICATIONS FOR THYROID CANCER CELL MIGRATION
AND PROLIFERATION. J Biol Chem. 2015 Jun;290(26):16116–31.
207. Shapovalov
G, Ritaine A, Skryma R, Prevarskaya N. Role of TRP ion channels in cancer and
tumorigenesis. Semin Immunopathol. 2016 May;38(3):357–69.
208. Wu H, Wang
H, Guan S, Zhang J, Chen Q, Wang X, et al. Cell-specific regulation of
proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2
status. Oncotarget. 2017 Oct;8(49):84996–5013.
209. Elbaz M,
Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser MW, et al. TRPV2 is a novel
biomarker and therapeutic target in triple negative breast cancer. Oncotarget.
2018 Sep;9(71):33459–70.
210. Badaoui M,
Mimsy-Julienne C, Saby C, Van Gulick L, Peretti M, Jeannesson P, et al.
Collagen type 1 promotes survival of human breast cancer cells by
overexpressing Kv10.1 potassium and Orai1 calcium channels through
DDR1-dependent pathway. Oncotarget. 2018 May;9(37):24653–71.
211. Potier M,
Chantome A, Joulin V, Girault A, Roger S, Besson P, et al. The SK3/K(Ca)2.3
potassium channel is a new cellular target for edelfosine. Br J Pharmacol. 2011
Jan;162(2):464–79.
212. Hall DP,
Cost NG, Hegde S, Kellner E, Mikhaylova O, Stratton Y, et al. TRPM3 and miR-204
establish a regulatory circuit that controls oncogenic autophagy in clear cell
renal cell carcinoma. Cancer Cell. 2014 Nov;26(5):738–53.
213. Song J, Wang
Y, Li X, Shen Y, Yin M, Guo Y, et al. Critical role of TRPC6 channels in the
development of human renal cell carcinoma. Mol Biol Rep. 2013
Aug;40(8):5115–22.
214. Kim JH,
Lkhagvadorj S, Lee MR, Hwang KH, Chung HC, Jung JH, et al. Orai1 and STIM1 are
critical for cell migration and proliferation of clear cell renal cell
carcinoma. Biochem Biophys Res Commun. 2014 May;448(1):76–82.
215. Rabjerg M,
Oliván-Viguera A, Hansen LK, Jensen L, Sevelsted-Møller L, Walter S, et al.
High expression of KCa3.1 in patients with clear cell renal carcinoma predicts
high metastatic risk and poor survival. PloS One. 2015;10(4):e0122992–e0122992.
216. Wang R,
Gurguis CI, Gu W, Ko EA, Lim I, Bang H, et al. Ion channel gene expression
predicts survival in glioma patients. Sci Rep. 2015 Aug;5:11593–11593.
217. Peng J, Ou
Q, Wu X, Zhang R, Zhao Q, Jiang W, et al. Expression of voltage-gated sodium
channel Nav1.5 in non-metastatic colon cancer and its associations with
estrogen receptor (ER)-β expression and clinical outcomes. Chin J Cancer. 2017
Nov;36(1):89–89.
218. Song P, Du
Y, Song W, Chen H, Xuan Z, Zhao L, et al. KCa3.1 as an Effective Target for
Inhibition of Growth and Progression of Intrahepatic Cholangiocarcinoma. J
Cancer. 2017;8(9):1568–78.
219. Ye Y, Yin M,
Huang B, Wang Y, Li X, Lou G. CLIC1 a novel biomarker of intraperitoneal
metastasis in serous epithelial ovarian cancer. Tumour Biol J Int Soc
Oncodevelopmental Biol Med. 2015 Jun;36(6):4175–9.
220. Yang SL, Cao
Q, Zhou KC, Feng YJ, Wang YZ. Transient receptor potential channel C3
contributes to the progression of human ovarian cancer. Oncogene. 2009
Mar;28(10):1320–8.
221. Gao R, Shen
Y, Cai J, Lei M, Wang Z. Expression of voltage-gated sodium channel alpha
subunit in human ovarian cancer. Oncol Rep. 2010 May;23(5):1293–9.
222. Farias LMB,
Ocaña DB, Díaz L, Larrea F, Avila-Chávez E, Cadena A, et al. Ether a go-go
potassium channels as human cervical cancer markers. Cancer Res. 2004
Oct;64(19):6996–7001.
223. Hernandez-Plata
E, Ortiz CS, Marquina-Castillo B, Medina-Martinez I, Alfaro A, Berumen J, et
al. Overexpression of NaV 1.6 channels is associated with the invasion capacity
of human cervical cancer. Int J Cancer. 2012 May;130(9):2013–23.
224. Arcangeli A,
Romoli MR, Boni L, Gerlini G, Tofani L, Urso C, et al. High hERG1 expression in
advanced melanoma. Melanoma Res. 2013 Jun;23(3):185–90.
225. Cao R, Meng
Z, Liu T, Wang G, Qian G, Cao T, et al. Decreased TRPM7 inhibits activities and
induces apoptosis of bladder cancer cells via ERK1/2 pathway. Oncotarget. 2016
Nov;7(45):72941–60.
226. Tian Y, Guan
Y, Jia Y, Meng Q, Yang J. Chloride intracellular channel 1 regulates prostate
cancer cell proliferation and migration through the MAPK/ERK pathway. Cancer
Biother Radiopharm. 2014 Oct;29(8):339–44.
227. Zhang GM,
Wan FN, Qin XJ, Cao DL, Zhang HL, Zhu Y, et al. Prognostic significance of the
TREK-1 K2P potassium channels in prostate cancer. Oncotarget. 2015
Jul;6(21):18460–8.
228. Diss JKJ,
Stewart D, Pani F, Foster CS, Walker MM, Patel A, et al. A potential novel
marker for human prostate cancer: voltage-gated sodium channel expression in
vivo. Prostate Cancer Prostatic Dis. 2005;8(3):266–73.
229. Lu J, Dong
Q, Zhang B, Wang X, Ye B, Zhang F, et al. Chloride intracellular channel 1
(CLIC1) is activated and functions as an oncogene in pancreatic cancer. Med
Oncol Northwood Lond Engl. 2015 Jun;32(6):616–616.
230. Yee NS, Chan
AS, Yee JD, Yee RK. TRPM7 and TRPM8 Ion Channels in Pancreatic Adenocarcinoma:
Potential Roles as Cancer Biomarkers and Targets. Scientifica.
2012;2012:415158–415158.
231. Yee NS,
Brown RD, Lee MS, Zhou W, Jensen C, Gerke H, et al. TRPM8 ion channel is
aberrantly expressed and required for preventing replicative senescence in
pancreatic adenocarcinoma: potential role of TRPM8 as a biomarker and target.
Cancer Biol Ther. 2012 Jun;13(8):592–9.
232. Chen CD,
Wang CS, Huang YH, Chien KY, Liang Y, Chen WJ, et al. Overexpression of CLIC1
in human gastric carcinoma and its clinicopathological significance.
Proteomics. 2007 Jan;7(1):155–67.
233. Xia J, Wang
H, Huang H, Sun L, Dong S, Huang N, et al. Elevated Orai1 and STIM1 expressions
upregulate MACC1 expression to promote tumor cell proliferation, metabolism,
migration, and invasion in human gastric cancer. Cancer Lett. 2016
Oct;381(1):31–40.
234. Xia J, Huang
N, Huang H, Sun L, Dong S, Su J, et al. Voltage-gated sodium channel Nav 1.7
promotes gastric cancer progression through MACC1-mediated upregulation of
NHE1. Int J Cancer. 2016 Dec;139(11):2553–69.
235. Ding XW,
Yang WB, Gao S, Wang W, Li Z, Hu WM, et al. Prognostic significance of hERG1
expression in gastric cancer. Dig Dis Sci. 2010 Apr;55(4):1004–10.
236. Selli C,
Erac Y, Kosova B, Erdal ES, Tosun M. Silencing of TRPC1 regulates
store-operated calcium entry and proliferation in Huh7 hepatocellular carcinoma
cells. Biomed Pharmacother Biomedecine Pharmacother. 2015 Apr;71:194–200.
237. Zhang S,
Wang XM, Yin ZY, Zhao WX, Zhou JY, Zhao BX, et al. Chloride intracellular
channel 1 is overexpression in hepatic tumor and correlates with a poor
prognosis. APMIS Acta Pathol Microbiol Immunol Scand. 2013 Nov;121(11):1047–53.
238. Liu Y, Zhao
L, Ma W, Cao X, Chen H, Feng D, et al. The Blockage of KCa3.1 Channel Inhibited
Proliferation, Migration and Promoted Apoptosis of Human Hepatocellular
Carcinoma Cells. J Cancer. 2015;6(7):643–51.
239. D’Alessandro
G, Catalano M, Sciaccaluga M, Chece G, Cipriani R, Rosito M, et al. KCa3.1
channels are involved in the infiltrative behavior of glioblastoma in vivo.
Cell Death Dis. 2013 Aug;4(8):e773–e773.
240. Chigurupati
S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, et al. Receptor
channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and
invasiveness. Cancer Res. 2010 Jan;70(1):418–27.
241. Bomben VC,
Sontheimer HW. Inhibition of transient receptor potential canonical channels
impairs cytokinesis in human malignant gliomas. Cell Prolif. 2008
Feb;41(1):98–121.
242. Lee YS,
Sayeed MM, Wurster RD. Inhibition of cell growth and intracellular Ca2+
mobilization in human brain tumor cells by Ca2+ channel antagonists. Mol Chem
Neuropathol. 1994 Jun;22(2):81–95.
243. Venturini E,
Leanza L, Azzolini M, Kadow S, Mattarei A, Weller M, et al. Targeting the
Potassium Channel Kv1.3 Kills Glioblastoma Cells. Neurosignals.
2017;25(1):26–38.
244. Huang L, Li
B, Tang S, Guo H, Li W, Huang X, et al. Mitochondrial KATP Channels Control
Glioma Radioresistance by Regulating ROS-Induced ERK Activation. Mol Neurobiol.
2015 Aug;52(1):626–37.
245. Visa A,
Sallán MC, Maiques O, Alza L, Talavera E, López-Ortega R, et al. T-Type Cav3. 1
channels mediate progression and chemotherapeutic resistance in glioblastoma.
Cancer Res. 2019;79(8):1857–68.
246. Liu S, Ba Y,
Li C, Xu G. Inactivation of CACNA1H induces cell apoptosis by initiating
endoplasmic reticulum stress in glioma. Transl Neurosci. 2023;14(1):20220285.
247. Valerie NC,
Dziegielewska B, Hosing AS, Augustin E, Gray LS, Brautigan DL, et al.
Inhibition of T-type calcium channels disrupts Akt signaling and promotes
apoptosis in glioblastoma cells. Biochem Pharmacol. 2013;85(7):888–97.
248. Mertens-Walker
I, Bolitho C, Baxter RC, Marsh DJ. Gonadotropin-induced ovarian cancer cell
migration and proliferation require extracellular signal-regulated kinase 1/2
activation regulated by calcium and protein kinase Cδ. Endocr Relat Cancer.
2010;17(2):335.
249. Bomben VC,
Turner KL, Barclay TC, Sontheimer H. Transient receptor potential canonical
channels are essential for chemotactic migration of human malignant gliomas. J
Cell Physiol. 2011;226(7):1879–88.
250. Cuddapah VA,
Turner KL, Sontheimer H. Calcium entry via TRPC1 channels activates chloride
currents in human glioma cells. Cell Calcium. 2013;53(3):187–94.
251. Richter JM,
Schaefer M, Hill K. Riluzole activates TRPC5 channels independently of PLC
activity. Br J Pharmacol. 2014;171(1):158–70.
252. Zeng J, Wu
Y, Zhuang S, Qin L, Hua S, Mungur R, et al. Identification of the role of TRPM8
in glioblastoma and its effect on proliferation, apoptosis and invasion of the
U251 human glioblastoma cell line. Oncol Rep. 2019;42(4):1517–26.
253. Caceres AI,
Liu B, Jabba SV, Achanta S, Morris JB, Jordt S. Transient receptor potential
cation channel subfamily M member 8 channels mediate the anti‐inflammatory
effects of eucalyptol. Br J Pharmacol. 2017;174(9):867–79.
254. Wang S, Li
X, Hu Y, Wang L, Lv G, Feng Y, et al. Discovery of N-alkyl-N-benzyl thiazoles
as novel TRPC antagonists for the treatment of glioblastoma multiforme. Eur J
Med Chem. 2024;265:116066.
255. Wan J, Guo
AA, King P, Guo S, Saafir T, Jiang Y, et al. TRPM7 induces tumorigenesis and
stemness through notch activation in glioma. Front Pharmacol. 2020;11:590723.
256. Yin H, Cheng
H, Li P, Yang Z. TRPC6 interacted with KCa1. 1 channels to regulate the
proliferation and apoptosis of glioma cells. Arch Biochem Biophys.
2022;725:109268.
257. Freeman S,
Elzamzamy O, Geldenhuys W, Hazlehurst L. CLIC1 is an Attractive Candidate for
the Initial Binding Target of the Novel Peptide MTI‐101. FASEB J.
2020;34(S1):1–1.
258. Xiong D,
Heyman NS, Airey J, Zhang M, Singer CA, Rawat S, et al. Cardiac-specific,
inducible ClC-3 gene deletion eliminates native volume-sensitive chloride
channels and produces myocardial hypertrophy in adult mice. J Mol Cell Cardiol.
2010;48(1):211–9.
259. Morelli MB,
Nabissi M, Amantini C, Maggi F, Ricci-Vitiani L, Pallini R, et al. TRPML2
Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and
Affect the Overall Survival in Glioblastoma Patients. Int J Mol Sci.
2022;23(23):15356.
260. Santoni G,
Maggi F, Amantini C, Arcella A, Marinelli O, Nabissi M, et al. Coexpression of
TRPML1 and TRPML2 Mucolipin Channels Affects the Survival of Glioblastoma
Patients. Int J Mol Sci. 2022;23(14):7741.
261. Mori A,
Lehmann S, O’Kelly J, Kumagai T, Desmond JC, Pervan M, et al. Capsaicin, a
component of red peppers, inhibits the growth of androgen-independent, p53
mutant prostate cancer cells. Cancer Res. 2006;66(6):3222–9.
262. Prevarskaya
N, Zhang L, Barritt G. TRP channels in cancer. Biochim Biophys Acta BBA-Mol
Basis Dis. 2007;1772(8):937–46.
263. Huang T, Xu
T, Wang Y, Zhou Y, Yu D, Wang Z, et al. Cannabidiol inhibits human glioma by
induction of lethal mitophagy through activating TRPV4. Autophagy.
2021;17(11):3592–606.
264. Yang W, Wu P
fei, Ma J xing, Liao M jun, Xu L shan, Yi L. TRPV4 activates the Cdc42/N-wasp
pathway to promote glioblastoma invasion by altering cellular protrusions. Sci
Rep. 2020;10(1):14151.
265. Thorneloe
KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, et al. An orally active
TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart
failure. Sci Transl Med. 2012;4(159):159ra148-159ra148.
266. Venturini E,
Leanza L, Azzolini M, Kadow S, Mattarei A, Weller M, et al. Targeting the
potassium channel Kv1. 3 kills glioblastoma cells. Neurosignals.
2018;25(1):26–38.
267. Grimaldi A,
D’Alessandro G, Di Castro MA, Lauro C, Singh V, Pagani F, et al. Kv1. 3
activity perturbs the homeostatic properties of astrocytes in glioma. Sci Rep.
2018;8(1):7654.
268. Leonard RJ,
Garcia ML, Slaughter RS, Reuben JP. Selective blockers of voltage-gated K+
channels depolarize human T lymphocytes: mechanism of the antiproliferative
effect of charybdotoxin. Proc Natl Acad Sci. 1992;89(21):10094–8.
269. Staudacher
I, Jehle J, Staudacher K, Pledl HW, Lemke D, Schweizer PA, et al. HERG K+
channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells.
PloS One. 2014;9(2):e88164.
270. Shugg T,
Dave N, Amarh E, Assiri AA, Pollok KE, Overholser BR. Letrozole targets the
human ether‐a‐go‐go–related gene potassium current in glioblastoma. Basic Clin
Pharmacol Toxicol. 2021;128(3):357–65.
271. Cherubini A,
Taddei G, Crociani O, Paglierani M, Buccoliero A, Fontana L, et al. HERG
potassium channels are more frequently expressed in human endometrial cancer as
compared to non-cancerous endometrium. Br J Cancer. 2000;83(12):1722–9.
272. Caramia M,
Sforna L, Franciolini F, Catacuzzeno L. The volume-regulated anion channel in
glioblastoma. Cancers. 2019;11(3):307.
273. Lv J, Liang
Y, Zhang S, Lan Q, Xu Z, Wu X, et al. DCPIB, an inhibitor of volume-regulated
anion channels, distinctly modulates K2P channels. ACS Chem Neurosci.
2019;10(6):2786–93.
274. Voss FK,
Ullrich F, Münch J, Lazarow K, Lutter D, Mah N, et al. Identification of LRRC8
heteromers as an essential component of the volume-regulated anion channel
VRAC. Science. 2014;344(6184):634–8.
275. Baker EM,
Thompson CH, Hawkins NA, Wagnon JL, Wengert ER, Patel MK, et al. The novel
sodium channel modulator GS‐458967 (GS 967) is an effective treatment in a
mouse model of SCN 8A encephalopathy. Epilepsia. 2018;59(6):1166–76.
276. Xing D, Wang
J, Ou S, Wang Y, Qiu B, Ding D, et al. Expression of neonatal Nav1. 5 in human
brain astrocytoma and its effect on proliferation, invasion and apoptosis of
astrocytoma cells. Oncol Rep. 2014;31(6):2692–700.
277. O’Hara T,
Rudy Y. Quantitative comparison of cardiac ventricular myocyte
electrophysiology and response to drugs in human and nonhuman species. Am J
Physiol-Heart Circ Physiol. 2012;302(5):H1023–30.
278. Ramaswamy P,
Dalavaikodihalli Nanjaiah N, Prasad C, Goswami K. Transcriptional modulation of
calcium‐permeable AMPA receptor subunits in glioblastoma by MEK–ERK1/2
inhibitors and their role in invasion. Cell Biol Int. 2020;44(3):830–7.
279. Arai A,
Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses
and behavior. Curr Drug Targets. 2007;8(5):583–602.
280. Partin KM,
Fleck MW, Mayer ML. AMPA receptor flip/flop mutants affecting deactivation,
desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate.
J Neurosci. 1996;16(21):6634–47.
281. Kim HJ, Kim
JY, Jung CW, Lee YS, An JY, Kim EH, et al. ANO1 regulates the maintenance of
stemness in glioblastoma stem cells by stabilizing EGFRvIII. Oncogene.
2021;40(8):1490–502.
282. Xuan Z bo,
Wang Y ji, Xie J. ANO6 promotes cell proliferation and invasion in glioma
through regulating the ERK signaling pathway. OncoTargets Ther. 2019;6721–31.
283. Britschgi A,
Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, et al. Calcium-activated
chloride channel ANO1 promotes breast cancer progression by activating EGFR and
CAMK signaling. Proc Natl Acad Sci. 2013;110(11):E1026–34.
284. Sheng Y, Wu
B, Leng T, Zhu L, Xiong Z. Acid-sensing ion channel 1 (ASIC1) mediates weak
acid-induced migration of human malignant glioma cells. Am J Cancer Res.
2021;11(3):997.
285. King P, Wan
J, Guo AA, Guo S, Jiang Y, Liu M. Regulation of gliomagenesis and stemness
through acid sensor ASIC1a. Int J Oncol. 2021;59(4):1–15.
286. Leng T, Si
H, Li J, Yang T, Zhu M, Wang B, et al. Amiloride Analogs as ASIC 1a Inhibitors.
CNS Neurosci Ther. 2016;22(6):468–76.
287. Kapoor N,
Lee W, Clark E, Bartoszewski R, McNicholas CM, Latham CB, et al. Interaction of
ASIC1 and ENaC subunits in human glioma cells and rat astrocytes. Am J
Physiol-Cell Physiol. 2011;300(6):C1246–59.
288. Chen WC, Kuo
TH, Tzeng YS, Tsai YC. Baicalin induces apoptosis in SW620 human colorectal
carcinoma cells in vitro and suppresses tumor growth in vivo. Molecules.
2012;17(4):3844–57.
289. Huang L, Li
B, Li W, Guo H, Zou F. ATP-sensitive potassium channels control glioma cells
proliferation by regulating ERK activity. Carcinogenesis. 2009;30(5):737–44.
290. Hattersley
AT, Ashcroft FM. Activating mutations in Kir6. 2 and neonatal diabetes: new
clinical syndromes, new scientific insights, and new therapy. Diabetes.
2005;54(9):2503–13.
291. Rafiq M,
Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT, et al. Effective
treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea
receptor 1 (SUR1) mutations. Diabetes Care. 2008;31(2):204–9.
292. D’Alessandro
G, Limatola C, Catalano M. Functional roles of the Ca2+-activated K+ channel,
KCa3. 1, in brain tumors. Curr Neuropharmacol. 2018;16(5):636–43.
293. Gribkoff VK,
Starrett Jr JE, Dworetzky SI. The Pharmacology and Molecular Biology of
Large-Conductance Calcium= Activated (BK) Potassium Channels. Adv Pharmacol.
1996;37:319–48.
294. Zhou Y,
Lingle CJ. Paxilline inhibits BK channels by an almost exclusively
closed-channel block mechanism. J Gen Physiol. 2014;144(5):415–40.
295. Ataga KI,
Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, et al. Efficacy
and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients
with sickle cell anemia. Blood J Am Soc Hematol. 2008;111(8):3991–7.
296. Zhou W, Liu
X, van Wijnbergen JWM, Yuan L, Liu Y, Zhang C, et al. Identification of PIEZO1
as a potential prognostic marker in gliomas. Sci Rep. 2020;10(1):16121.
297. Chen X,
Wanggou S, Bodalia A, Zhu M, Dong W, Fan JJ, et al. A feedforward mechanism
mediated by mechanosensitive ion channel PIEZO1 and tissue mechanics promotes
glioma aggression. Neuron. 2018;100(4):799–815.
298. Bae C, Sachs
F, Gottlieb PA. The mechanosensitive ion channel Piezo1 is inhibited by the
peptide GsMTx4. Biochemistry. 2011;50(29):6295–300.
299. Kurata T,
Rajendran V, Fan S, Ohta T, Numata M, Fushida S. NHE5 regulates growth factor
signaling, integrin trafficking, and degradation in glioma cells. Clin Exp
Metastasis. 2019;36:527–38.
300. Ko M, Makena
MR, Schiapparelli P, Suarez-Meade P, Mekile AX, Lal B, et al. The endosomal pH
regulator NHE9 is a driver of stemness in glioblastoma. PNAS Nexus.
2022;1(1):pgac013.
301. Pall AE,
Juratli L, Guntur D, Bandyopadhyay K, Kondapalli KC. A gain of function
paradox: Targeted therapy for glioblastoma associated with abnormal NHE9
expression. J Cell Mol Med. 2019;23(11):7859–72.
302. Luo L, Wang
J, Ding D, Hasan MN, Yang SS, Lin SH, et al. Role of NKCC1 activity in glioma
K+ homeostasis and cell growth: New insights with the bumetanide-derivative
STS66. Front Physiol. 2020;11:911.
303. Blaesse P,
Airaksinen MS, Rivera C, Kaila K. Cation-chloride cotransporters and neuronal
function. Neuron. 2009;61(6):820–38.
304. Nieto FR,
Cobos EJ, Tejada MÁ, Sánchez-Fernández C, González-Cano R, Cendán CM.
Tetrodotoxin (TTX) as a therapeutic agent for pain. Mar Drugs. 2012
Feb;10(2):281–305.
305. Challapalli
V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of
local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst
Rev. 2019 Oct;2019(10).
306. Brinkrolf P,
Hahnenkamp K. Systemic lidocaine in surgical procedures: effects beyond sodium
channel blockade. Curr Opin Anaesthesiol. 2014 Aug;27(4):420–5.
307. McCann G.
Pharmacological treatment of significant cardiac arrhythmias. Br J Sports Med.
2000 Oct;34(5):401–2.
308. Fairhurst C,
Martin F, Watt I, Doran T, Bland M, Brackenbury WJ. Sodium channel-inhibiting
drugs and cancer survival: protocol for a cohort study using the CPRD primary
care database. BMJ Open. 2016 Sep;6(9):e011661–e011661.
309. Doty P, Rudd
GD, Stoehr T, Thomas D. Lacosamide. Neurother J Am Soc Exp Neurother. 2007
Jan;4(1):145–8.
310. Mantegazza
M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as
therapeutic targets in epilepsy and other neurological disorders. Lancet
Neurol. 2010 Apr;9(4):413–24.
311. Black JA,
Waxman SG. Phenytoin protects central axons in experimental autoimmune
encephalomyelitis. J Neurol Sci. 2008 Nov;274(1–2):57–63.
312. Perucca E. A
pharmacological and clinical review on topiramate, a new antiepileptic drug.
Pharmacol Res. 1997 Apr;35(4):241–56.
313. Silke B,
Goldhammer E, Sharma SK, Verma SP, Taylor SH. An exercise hemodynamic
comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.
Cardiovasc Drugs Ther. 1990 Apr;4(2):457–63.
314. Rubaiy HN.
The therapeutic agents that target ATP-sensitive potassium channels. Acta Pharm
Zagreb Croat. 2016 Mar;66(1):23–34.
315. Sanguinetti
MC, Bennett PB. Antiarrhythmic drug target choices and screening. Circ Res.
2003 Sep;93(6):491–9.
316. Ravens U,
Poulet C, Wettwer E, Knaut M. Atrial selectivity of antiarrhythmic drugs. J
Physiol. 2013 Sep;591(17):4087–97.
317. Michiels CF,
Van Hove CE, Martinet W, De Meyer GRY, Fransen P. L-type Ca2+ channel blockers
inhibit the window contraction of mouse aorta segments with high affinity. Eur
J Pharmacol. 2014 Sep;738:170–8.
318. Lukasova M,
Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression
of atherosclerosis in mice through its receptor GPR109A expressed by immune
cells. J Clin Invest. 2011 Mar;121(3):1163–73.
319. Ashcroft SJ,
Ashcroft FM. Properties and functions of ATP-sensitive K-channels. Cell Signal.
1990;2(3):197–214.
320. Jang SH,
Choi SY, Ryu PD, Lee SY. Anti-proliferative effect of Kv1.3 blockers in A549
human lung adenocarcinoma in vitro and in vivo. Eur J Pharmacol. 2011
Jan;651(1–3):26–32.
321. Borrelli F,
Pagano E, Romano B, Panzera S, Maiello F, Coppola D, et al. Colon
carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a
Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014
Dec;35(12):2787–97.
322. Huang MH,
Huang YM, Wu SN. The Inhibition by Oxaliplatin, a Platinum-Based
Anti-Neoplastic Agent, of the Activity of Intermediate-Conductance Ca2+-Activated
K+ Channels in Human Glioma Cells. Cell Physiol Biochem Int J Exp
Cell Physiol Biochem Pharmacol. 2015;37(4):1390–406.
323. Djamgoz MBA,
Onkal R. Persistent current blockers of voltage-gated sodium channels: a
clinical opportunity for controlling metastatic disease. Recent Patents
Anticancer Drug Discov. 2013 Jan;8(1):66–84.
324. Brackenbury
WJ, Chioni AM, Diss JKJ, Djamgoz MBA. The neonatal splice variant of Nav1.5
potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer
cells. Breast Cancer Res Treat. 2007 Jan;101(2):149–60.
325. Yavuz M,
Şahin B, Baykal AT, Demircan T. Hydroquinidine displays a significant
anti-carcinogenic activity in breast and ovarian cancer cells via inhibiting
cell-cycle and stimulating apoptosis. Turk J Biol. 2023;47(1):44–60.
326. Dao Trong P,
Jungwirth G, Unterberg A, Herold-Mende C, Warta R. The Antiepileptic Drug
Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase
Mutant Glioma Stem-like Cells. Cells. 2023;12(8):1200.
327. Dong W,
Fekete A, Chen X, Liu H, Beilhartz GL, Chen X, et al. A designer peptide
against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells
and neurons to treat glioblastoma. Nat Cancer. 2023;4(10):1418–36.
328. Mlayah-Bellalouna
S, Aissaoui-Zid D, Chantome A, Jebali J, Souid S, Ayedi E, et al. Insights into
the mechanisms governing P01 scorpion toxin effect against U87 glioblastoma
cells oncogenesis. Front Pharmacol. 2023;14:1203247.
329. Dinevska M,
Gazibegovic N, Morokoff AP, Kaye AH, Drummond KJ, Mantamadiotis T, et al.
Inhibition of radiation and temozolomide-induced glioblastoma invadopodia
activity using ion channel drugs. Cancers. 2020;12(10):2888.
330. Luo L, Wang
J, Ding D, Hasan MN, Yang SS, Lin SH, et al. Role of NKCC1 activity in glioma
K+ homeostasis and cell growth: New insights with the bumetanide-derivative
STS66. Front Physiol. 2020;11:911.
331. Huang T, Xu
T, Wang Y, Zhou Y, Yu D, Wang Z, et al. Cannabidiol inhibits human glioma by
induction of lethal mitophagy through activating TRPV4. Autophagy.
2021;17(11):3592–606.